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ABSTRACT OF THE DISSERTATION 
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Professor Sakhrat Khizroev, Major Professor 
 
A major challenge of cancer treatment is successful discrimination of cancer cells from 
healthy cells. Nanotechnology offers multiple venues for efficient cancer targeting. 
Magnetoelectric nanoparticles (MENs) are a novel, multifaceted, physics-based cancer 
treatment platform that enables high specificity cancer targeting and externally controlled 
loaded drug release. The unique magnetoelectric coupling of MENs allows them to 
convert externally applied magnetic fields into intrinsic electric signals, which allows 
MENs to both be drawn magnetically towards the cancer site and to electrically interface 
with cancer cells. Once internalized, the MEN payload release can be externally triggered 
with a magnetic field. MENs uniquely allow for discrete manipulation of the drug 
delivery and drug release mechanisms to allow an unprecedented level of control in 
cancer targeting. In this study, we demonstrate the physics behind the MEN drug delivery 
platform, test the MEN drug delivery platform for the first time in a humanized mouse 
model of cancer, and characterize the biodistribution and clearance of MENs. We found 
vii 
that MENs were able to fully cure the model cancer, which in this case was human 
ovarian carcinoma treated with paclitaxel. When compared to conventional magnetic 
nanoparticles and FDA approved organic PLGA nanoparticles, MENs are the highest 
performing treatment, even in the absence of peripheral active targeting molecules. We 
also mapped the movement through peripheral organs and established clearance trends of 
the MENs. The MENs cancer treatment platform has immense potential for future 
medicine, as it is generalizable, personalizable, and readily traceable in the context of 
treating essentially any type of cancer. 
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CHAPTER 1: INTRODUCTION 
1.1 General Introduction 
Cancer is one of leading causes of death worldwide, with 8.2 million deaths and 
14 million new cases reported in 2012, and an expected number of 22 million new cancer 
cases within the next two decades [1]. In the United States, over a third of the population 
is expected to be diagnosed with cancer in their lifetime and in 2016 an estimated 
595,690 people are predicted to die a cancer-related death while an estimated 1,685,210 
new cases are predicted to arise [2]. Although cancer treatment options have both 
increased in quantity and improved in quality recently, there is still much work to be done 
to improve overall cancer survivability and quality of life while patients undergo cancer 
treatment. In fact, this year, the Obama Administration launched a billion dollar initiative 
called the National Cancer “Moonshot” initiative, which aims to greatly accelerate the 
speed  and progress of cancer research to make more therapies available to more patients 
sooner [3]. This federal “Moonshot” directive highlights the urgency and priority that is 
currently placed on translatable cancer research. 
Despite countless advances in cancer medicine, cancer treatment is still a huge 
challenge for researchers, health care providers, and patients alike. Unlike treating a 
microbial infection, where a discrete invader or unruly cohabitant is the source of illness, 
cancer poses the unique challenge of being almost indistinguishable from the rest of the 
organism. Cancer cells are a diseased version of the self, making isolating them for 
treatment extraordinarily difficult. Thus, cancer treatment depends on more subtle 
differences between the healthy cells and cancer cells (in comparison to the extensive 
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differences between prokaryotic cells and eukaryotic cells in a bacterial infection, for 
example) for drug targeting. 
While the cell biology of cancer does differ from that of healthy cells, it remains a 
challenge to effectively exploit these differences in practical applications regarding 
treatment and monitoring. Nanotechnologies offer a unique assortment of tools to help 
capitalize on some of the fundamental differences of cancerous tissues. A brief timeline 
of the history of nanoparticles shows that nanoparticles have existed in nature long before 
humans, nanomaterials have been primitively utilized by humans for thousands of years 
with more advanced uses emerging hundreds of years ago, and the principles of 
nanomaterial properties have only been understood by humans for decades [4]. Modern 
day nanoparticles are reliably synthesized to come in a wide variety of formulations (and 
therefore properties) and are typically 1-100 nm in size, but can be anywhere between 
over a nanometer and under a micron. Nanoparticle treatments and treatment delivery 
systems are a very promising and exciting platform for cancer treatment. Nanoparticle 
based cancer treatment systems can complement, improve, or even entirely replace 
conventional cancer treatments.  
1.2 Study Motivation 
Our group has pioneered the application of a new class of nanoparticles, 
magnetoelectric nanoparticles (MENs), to biomedical sciences. This unique inorganic 
nanoparticle, which exhibits strong magneto-electric coupling (discussed in Chapter 2), 
opens the door to a plethora of medical applications. We have already demonstrated the 
use of MENs as customizable drug-delivery platforms (discussed in Chapter 3) and deep-
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brain stimulation platforms [5], [6], and are currently working on other novel applications 
of this technology.  
One of our primary goals is to develop a cancer therapy that can universally be used 
for the majority of cancer patients. The ideal cancer therapy would be customizable based 
on specific patient needs, but would rely on generally applicable properties of cancer 
anatomy and physiology to be relevant to all but the most unique cases. Such a treatment 
would have minimal side effects and would also, ideally, be readily imaged for 
monitoring the treatment. We believe that MENs have the potential to be the ideal cancer 
treatment because the MENs nanomedicine platform conforms to the ideals of being (a) 
generalizable to almost any cancer, (b) highly specific to cancer, thereby reducing side 
effects, and (c) readily imaged with current technology.  
This dissertation focuses on the application of MENs as a highly targeted and 
controlled drug delivery and release platform for the treatment of cancer. We wanted to 
demonstrate three main concepts in the scope of this dissertation work:  
1. Confirm that MENs are able to discriminately enter cancer cells (while avoiding 
healthy cells) by crossing the cell membrane to reach the cytoplasm with the 
payload intact when influenced by an externally applied magnetic field (Chapter 
4). 
2. Test the MEN cancer drug delivery platform for the first time in a mouse model to 
establish the successful translation of the treatment from in-vitro to in vivo 
(Chapter 5). 
3. Establish the biodistribution and clearance patterns of MENs in the mouse model 
(Chapter 6). 
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CHAPTER 2: INTRODUCTION TO CANCER & NANOMEDICINE 
2.1 Introduction 
The scope of this literature review covers the relevant aspects of cancer that are 
commonly exploited by nanotechnology for cancer treatment and the nanotechnologies 
currently utilized for this purpose. Specifically, the formation of the enhanced 
permeability and retention effect will be discussed, as it is pertinent to all nanomedicines. 
Active targeting by means of surface molecules is also introduced. Then, both organic 
and inorganic nanotechnologies will be briefly introduced in the context of their drug 
delivery capabilities and cancer treatment potentials. 
2.2 Cancer Physiology and Clinical Treatment Options 
2.2.1 Current Cancer Treatments 
While the total incidence rates of cancer are still climbing, the treatment options 
and survival rates are growing as well. Indeed, cancer related death rates have been 
falling on average 1.5% each year between 2004-2013 and the 5 year survival has 
increased  to 68.9% in 2008 compared to 48.7% in 1975 [2], [7]. Cancer is no longer the 
death sentence it used to be, but is still associated with morbidity from cancer therapies. 
Table 1 summarizes the National Institute of Health (NIH): National Cancer Institute 
(NCI) classifications of the main categories of current clinical cancer treatments.  
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Table 1. NCI classifications of cancer treatments.  
Treatment Type Description Main Limitations 
Surgery Tumor excision via manual 
removal or tumor destruction 
via freezing, heating, laser, or 
photodynamic therapy. 
Only applicable to well 
contained tumors at known and 
accessible locations.  
Radiation 
Therapy 
External or internal application 
of high doses of radiation to 
attack cancer cells. 
Extensive healthy cell damage 
related side effects. 
Chemotherapy Using pharmaceutical agents to 
chemically attack cancer cells.
  
Extensive healthy cell damage 
related side effects. 
Targeted 
Therapy 
Exploits the unique cellular 
properties of cancers to develop 
very specific treatments. 
Challenging drug development 
process due to extensive possible 
targets; development of 
treatment resistance; side effects 
from healthy cell off-targeting. 
Hormone 
Therapy 
(Targeted 
Therapy Subtype) 
Modifying the patient’s 
hormones to reduce hormones 
beneficial to cancer. 
Only applicable to cancers 
strongly associated with 
hormones; hormone imbalance 
related side effects. 
Immunotherapy 
(Targeted 
Therapy Subtype) 
Assisting the patient’s own 
immune system to attack cancer 
cells using monoclonal 
antibodies, cytokines, adoptive 
T cell transfer, or other 
biological methods. 
Use not as widespread as other 
therapies; immune response 
related side effects.  
  
The numerous treatments available provide many options for cancer patients. 
Surgery is a good course of action when possible; however, it is simply not an option for 
every cancer type and extent of progression. Chemotherapy [8], [9] and radiation therapy 
[10]–[12] can also be very effective treatments, but typically at the cost of extensive 
collateral damage to healthy cells that result in considerable side effects. Targeted 
therapy [13], therefore, provides an attractive option for treatment in that it leads to 
“precision medicine” by using targets unique to cancer [14]–[16]. It provides higher 
specificity to cancer cells to reduce side effects and can be tailored to potentially any 
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cancer with enough research into cancer biomarkers or any other targetable components. 
This new level of specificity for cancer cells will improve upon the already established, 
albeit weaker, specificity of conventional treatments. 
Considering that one of the most important defining parameters of cancer cells is 
their unrestricted growth and division, the processes of halting new DNA synthesis, 
destroying existing DNA, and interfering with mechanisms of mitosis are frequently 
investigated for anti-tumor potential [17]. There are numerous drug options for mitotic 
inhibitors (including: microtubule stabilizers, kinetochore, centromere, and centrosome 
interferes; other mitotic cytoplasm protein binders) each of which can lead to cell death 
or an alternative pathway that halts cellular division and progress [17]–[19]. While this 
type of drug is still cytotoxic to healthy cells, the uncontrolled division characteristic of 
cancer cells will make them more heavily affected than regular, slow-dividing cells. 
Normal rapidly dividing non-cancerous cells, like hair follicles, tend to also be noticeably 
affected in these treatments, resulting in the hair loss associated with undergoing cancer 
treatment.  
Another distinctive feature of tumors is their recruitment of new blood vessels to 
maintain perfusion for the growing mass of cancer cells. Angiogenesis in general is 
directed by a local balance of promoters and inhibitors [20], [21]. In the case of many 
cancers (as well as healthy, normally angiogenic tissues like ovarian follicles), the net 
balance is heavier on angiogenic promoters than on inhibitors, thereby causing nearby 
blood vessels to sprout growth into the tissue. Tumors that fail to recruit new blood 
vessels are typically stunted in growth by the limiting factor of nutrient diffusion from 
nearby vessels. These under-perfused tumors exhibit necrosis in areas where growth has 
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exceeded the influence of nutrient diffusion, and will maintain a relatively stable size as 
cells further away from the nutrient source die off. Likewise, tumors located sufficiently 
far from blood vessels are less capable of disseminating into circulation and tend to 
remain in a benign state. Thus, anti-angiogenic drugs are another good treatment option 
in that they hinder the growth potential of the tumor [22]. 
Compared to drugs targeted to unique functions of cancers like rapidly mitotic 
division or angiogensis, nanocarriers allow for even fewer unintended recipients of the 
drugs by establishing greater directing power to cancer cells and away from healthy cells 
(like the naturally rapidly dividing hair follicles or the periodically angiogenic ovarian 
follicles, for example). Nanocarriers also allow for a smaller drug dose to be used for the 
desired effect, as less of the drug is lost en route and, therefore, fewer side effects are 
incurred from having bioavailable drug in the physiological system. Furthermore, if a 
reliable drug binding is accomplished until the designated target is reached with high 
specificity, other generally cytotoxic agents can potentially be used to treat a variety of 
cancers. This would greatly increase the drug options beyond those that do not 
overwhelmingly affect healthy cells into potentially more potent cancer cell eliminators. 
2.2.2 Active & Passive Drug Delivery 
The enhanced permeability and retention (EPR) effect is a unique characteristic of 
tumors that arises from the combination of malformed vascular and lymphatic vessels. 
This allows macromolecules to both enter and linger inside tumors, making it exploitable 
to improve treatment delivery [23].  The vasculature of tumors is unique in several ways 
[24]. First, these vessels lack the typical architecture of branching larger vessels into 
smaller ones with regular spacing, and are prone to collapse by crushing from 
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neighboring proliferating tumor cells.  This causes an irregular arterial to venous pressure 
difference which slows down blood flow in the vessels and lowers the perfusion of 
surrounding tissue. Secondly, the cellular composition of tumor vasculature is different in 
that there are wide inter-endothelial junctions along with a surplus of vesicular 
transendothelial channels and fenestrations. These pores in the vasculature can be up to 
several hundred nanometers wide, and contribute to the “leaky” property of tumor blood 
vessels. Tumors also lack an adequate lymphatic drainage system, forcing 
macromolecules to accumulate at the site of the perforation [25]. Proliferating cancer 
cells crush and collapse existing lymphatic vessels [23], and unlike the characteristic 
promotion of angiogenesis by cancer cells to maintain perfusion, lymphatic vessels are 
not sufficiently regenerated in cancerous tissue to maintain adequate lymphatic drainage.  
The enhanced permeability of tumor vasculature is coupled with the retention 
caused by inadequate lymphatic drainage to cause the EPR effect, which can allow cancer 
therapies of the correct size and properties to accumulate inside tumors [26]. This type of 
drug delivery is considered passive, relying on inherent properties of the tumor macro-
environment. By comparison, active targeting relies on molecule-facilitated guidance to 
specific components unique to the surfaces of diseased cells. Immunological agents such 
as monoclonal antibodies [27] or other ligands are selected to have high specificity for 
cancer markers, and can actively seek out cancer cells for drug delivery [28]. Compared 
to EPR, active targeting allows for smaller cell masses to be targeted, but requires a more 
complex design to have a strong enough affinity for an antigen that is consistently present 
on cancer and absent on healthy cells. The heterogeneity of cancer cells between 
individuals and even within the same individual must be considered when selecting an 
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active targeting molecule, making a fully comprehensive cancer treatment a challenge to 
develop using immunotherapy-assisted drug targeting exclusively [29]. 
Nanoparticles are very effective exploiters of the EPR mechanism and can be 
used to passively accumulate drugs inside tumors. Likewise, nanoparticles can be 
formulated to actively target cancer-specific molecules for drug delivery. Combining the 
passive and active targeting approaches can lead to even better localization of drugs into 
tumor cells [30].  
2.3 Organic Nanoparticles: Drug Delivery Platforms 
 Organic nanoparticles can be synthetic or natural in origin. They have been 
accepted in biomedical applications for longer than inorganic particles and are favored 
with respect to having no biocompatibility or retention issues. However, the trade-off for 
these fully biocompatible properties is a very quick release of their contents due to the 
inherent capacity to break down in the biological system to which the particles are 
introduced. Even though there is minimal control of when organic nanoparticles 
decompose and trigger their payload release, they do offer a considerable improvement 
compared to utilizing free-drug. 
Liposomes are one of the oldest nanoparticle drug carriers designed to improve 
pharmacokinetics and biodistribution [23]. Liposomes are composed of various lipids in a 
mono- or bi-layer forming a spherical vesicle surrounding an aqueous core. They can be 
designed to range greatly in size (from about 10 nm to over 1 µm) and in surface 
properties, like charge and functionality, using varied combinations of commercially 
available lipids [31]. Another benefit of the aqueous core surrounded by a layer of lipid 
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structure is that both hydrophilic and hydrophobic drugs can be loaded into each 
compartment, respectively. However, liposomes suffer from a low encapsulation 
capacity, poor drug solubility, and instability in the bloodstream that leads to a very 
quick-burst release of loaded drugs. Some of these shortcomings can be addressed with 
functionalized coatings, like polyethylene glycol (PEG), which will increase the stability 
and circulation half-life of the liposomes [32]. However, even uncoated liposomes 
already offer an improvement over the half-life of free drug. 
Polymeric nanoparticles are composed of various polymers such as poly (lactic acid), 
poly(D,L-lactic-co-glycolic acid) (PLGA), dextran, chitosan, etc [33]. These polymers 
are biocompatible and tend to be biodegradable into the monomer units, which can then 
be metabolized normally by the body. The degradation process will release the drugs 
encapsulated inside. The rate of degradation and, therefore, the drug kinetics are 
determined by the polymeric nanoparticle design aspects such as hydrophobicity, size, 
dispersity index, and crystallinity [31]. Polymeric nanoparticles tend to be relatively 
stable due to the hydrophilic shell providing steric protection to the nanoparticle while 
the hydrophobic core holds a high capacity of the drug to be delivered [23]. Another 
benefit is that a wide variety of drugs can be loaded inside polymeric nanoparticles, 
including small molecules of both hydrophobic or hydrophilic varieties and even 
macromolecules such as nucleic acids or proteins [34]. Polymeric nanoparticles can also 
be given a functionalized surface coating, such as PEG, to further modify their 
physiological properties.  
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Micelles can also be a type of polymeric nanoparticles, however they can also be made 
entirely from lipids, similar to liposomes [35]. Micelles tend to range from 10-100 nm 
and are composed of a hydrophobic core surrounded by amphiphilic surfactant molecules 
[36]. The key difference between liposomes and lipid micelles is that micelles lack the 
aqueous core of liposomes and are instead designed specifically to hold hydrophobic 
drugs.  
Dendrimers are branched macromolecules composed of monomers such as nucleotides, 
amino acids, or sugars from natural or synthetic sources [23]. Dendrimers can be 
designed to conjugate to drugs through hydrophobic interactions, hydrogen bonds, or 
chemical linkages within the cavities of the core created by the branching architecture. 
The surface can also contain functional groups for further modification. Dendrimers tend 
to be small (5-10 nm) and globular structures with notable monodispersity, where the 
drug release kinetics can be readily controlled through the cleavable chemistry in the 
polymer chains [31]. 
Protein nanoparticles are also an attractive drug delivery platform due to the extensive 
functionalities and the fully biodegradable and metabolizable nature of natural proteins. 
Protein nanoparticles can readily interact with both drug and solvent due to their 
amphiphilicity, and have modifiable surfaces onto which a wide variety of drugs and 
targeting molecules can be attached [37]. One of the most commonly studied protein 
nanoparticles is albumin (of both bovine and human serum), which is a natural soluble 
carrier of endogenous hydrophobic molecules. Other water soluble protein nanoparticles 
include gelatin, elastin, and soy proteins. Insoluable proteins are also available in the 
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forms of gliadin, legumin, and zein. One of the major benefits of food-based protein 
nanoparticles, such as milk and whey derived nanoparticles, is that the materials are 
readily available and easy to formulate, and that there already exists extensive knowledge 
on the safety of their use.  
Biological nanoparticles utilize existing uniceulluar organisms such as bacteria to serve 
as drug carriers [31]. A biological cell offers many options for loading drugs of various 
solubilities and charges, and an intact cell offers considerable stability in physiological 
conditions. While this delivery platform is liable to induce an immunological response 
when administered, the removal of the nucleus ensures no pathogenic activity of the 
drug-loaded cell.  
2.4 Inorganic Nanoparticles: Drug Carriers, Imaging Tools, and Treatment Agents 
Inorganic nanoparticles are mostly composed of an inert metal substance that is 
biocompatible, with all other properties being dependent on the exact metals in the 
formulation. Arguably, the most significant benefit of metal nanoparticles is the triple-
treatment potential: imaging, drug delivery, and inherent cancer cell cytotoxicity. Similar 
to their organic nanoparticle counterparts, inorganic nanoparticles can be drug loaded and 
functionally coated for passive and active drug delivery. However, they have the added 
benefit of being readily traceable through medical imaging technology and of being 
uniquely cytotoxic to cancer cells with or without extrinsic stimulation. The generation of 
heat or reactive oxygen species, for instance, places metal nanoparticles into a distinctive 
treatment class that can further be augmented with the same drug delivery aspects as 
other nanoparticles types.  
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2.4.1 Metal nanoparticles (Weakly or Non –Magnetic) 
In this section, metal nanoparticles refer to particles composed of weakly or non-
magnetic metals that are used for cancer treatment. These nanoparticles are usually 
formulated from the frequently studied noble metals (i.e. gold and silver) or zinc based 
compounds, but can also be made of numerous other, generally non-magnetic metals, 
including, but not limited to, silicon, cerium, barium, bismuth, calcium, copper, 
magnesium, and titanium [38], [39]. The following section is a summary of some of the 
functional highlights of zinc, gold, and silver nanoparticles in regards to cancer treatment 
selected from the extensive and well-written Sharma et al. review [38]. 
Zinc Oxide nanoparticles can be imaged based on their inherent 
photoluminescence. These particles are also strong reactive oxygen species 
generators due to the wide band-gap semiconductor nature of the crystalline 
structure, which allows electrons to travel between gaps and create unoccupied 
states (H+). Both the electrons and the electron holes diffuse to the particle 
surface where superoxide and hydroxyl radicals are created upon the reaction of 
oxygen with electrons, and hydroxyl ions with the electron holes, respectively. 
The generation of reactive oxygen species is further instigated by the application 
of ultraviolet light, making for an even more potent cytotoxicity at a targeted site. 
Gold nanoparticles can readily be followed in a biological system using 
multiple imaging platforms including optical imaging, magnetic resonance 
imaging (MRI), computed tomography, photoacoustic imaging, and flow 
cytometry.  They are also valuable in photothermal therapy, where an extrinsic 
application of energy causes localized heating through the nanoparticles. This is 
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because gold nanoparticles are an example of a plasma metal, where the 
nanoparticle system has an equal number of fixed positive ions and mobile 
conduction electrons, which will result in an oscillating electron charge in 
resonance with visible light frequency when irradiated with an electromagnetic 
wave. The size of the gold nanoparticle determines the extent of the energy loss in 
the form of scattering and absorption. Larger particles have a higher scattering 
efficiency that makes them superior for imaging, while smaller particles are better 
absorbers and are therefore preferred for their effective conversion of energy into 
heat in photothermal therapy. In addition to effective photothermal conversion for 
hyperthermic destruction, gold nanoparticles are also radiosensitizers, allowing 
radiation therapy to work more effectively on cancer cells.  
Silver nanoparticles have similar plasmonic features to gold, making them 
comparably effective at absorbing and scattering applied light for imaging and 
photothermal therapy, respectively. However, silver has a higher plasmon 
excitation efficiency and has a plasmon resonance that can be tuned to any visible 
light wavelength. Another unique feature of silver nanoparticles is their 
neutralization of glutathione and thioredoxin, which are the primary reactive 
oxygen species neutralizing proteins. This destruction of antioxidant defenses will 
allow an accumulation of reactive oxygen species that can ultimately cause 
enough damage to induce cell death. 
Finally, mesoporous silica nanoparticles are also an inorganic nanoparticle class 
which offers unique utilities. Characterized by their highly customizable pores, 
mesoporous silica nanoparticles offer extensive surface area and volume within the pores 
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for stable, high encapsulation capacity drug loading while maintaining biocompatibility 
and controlled release mechanisms [40]. The dissolution of the encapsulated drugs from 
mesoporous silica nanoparticles is preferable over the organic nanoparticle counterparts’ 
in that the payload is maintained in amorphous or noncrystaline states in the chemically 
stable and inert nanocarrier [41]. Furthermore, mesoporous silica nanoparticles can be 
tagged with fluorescent agents for fluorescent bioimaging or formulated to incorporate 
MRI contrast agent nanoparticles, without or without further ligand targeting to specific 
tissue sites, for MRI imaging. 
2.4.2 Ferromagnetic Metal Nanoparticles 
Ferromagnetic nanoparticles are a subtype of nanoparticles that can be classified 
as having a significantly magnetic nature. These particles are typically made of iron, but 
can also be fully or partially composed of nickel or cobalt. Like other metal 
nanoparticles, ferromagnetic particles can be (a) functionalized for molecular targeting, 
(b) drug-loaded, and (c) drug-free tumor treatments in the form of hyperthermia or 
reactive oxygen species generation in response to non-toxic wavelength radiation. The 
unique benefit of magnetic metal based nanoparticles is the sensitivity to magnetic fields, 
which can be safely applied externally to induce the selective cytotoxic effects in addition 
to external directing of nanoparticles to target sites [42]. Likewise, a permanent magnet 
can be non-invasively implanted for a constant pull of magnetic nanoparticles to a more 
internally located tumor and can then be safely removed upon completion of the 
treatment. Other than active molecular targeting and administration in the vicinity of the 
tumor site when possible, there is little that can be done to help direct nanoparticle 
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treatments to their intended destination post-administration. The EPR effect can be 
complemented with strategically placed magnetic fields, and magnetic field gradients can 
be used to create a customized attraction of magnetic nanoparticles to the intended 
treatment region [43].  
Some of the most commonly studied ferromagnetic materials are iron oxides, 
especially magnetite (Fe2O4), which occurs naturally in both prokaryotic and eukaryotic 
organisms for magnetic field sensing [44]. Magnetite has unique physical properties (i.e. 
magnetics based on a small size with large surface area) that make it well suited for 
biological applications [45], and it is readily synthesized to be biocompatible [46]. While 
there is some concern for ferromagnetic aggregation of magnetic nanoparticles, this can 
be addressed with careful magnetization of the particles. Unlike the constant 
magnetization of bulk iron, super paramagnetic iron oxide nanoparticles (SPIONs) are 
used precisely because they exhibit a magnetism of zero when not under the effect of a 
magnetic field [38], [47]. This allows for the magnetic properties of the particles to be 
activated only when needed (i.e. when at the tumor site instead of when traveling through 
the blood).  When SPIONs are unaffected by a field, there are random fluctuations in the 
magnetization direction of each particle caused by the thermal energy overcoming the 
coupling forces between neighboring particles above the Curie temperature [43]. As each 
particle shifts its magnetic moment to align with an applied magnetic field, the overall 
magnetic moment of the particles collectively is no longer null and an overall 
polarization is established. The magnetization can then be returned to zero immediately 
by applying a field of equal strength in the negative direction, or it will return slowly if 
the magnetic field is simply removed, as a spontaneous random orientation of 
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nanoparticle magnetic spins is achieved over time. This principal ensures that no 
agglomeration will occur before the particles localize at the site and after treatment is 
complete.  
If alternating external magnetic fields are applied, heat is released as the particles 
lose energy from the quick reorientation of the magnetic dipoles proportional to the 
strength and frequency of the applied field. This makes magnetic nanoparticles well 
suited to magnetic field induced hyperthermia treatment [48], [49]. In fact, hematite 
(Fe2O3) particles have been used to thermally treat metastasized cancers in the lymph 
nodes almost 60 years ago [50]. Furthermore, mild hyperthermia is synergistic with other 
treatment types, making a nanoparticle that induces hyperthermia and delivers a 
secondary treatment highly desirable [51].  While larger particle sizes result in higher 
saturation magnetization values and therefore stronger magnetic hyperthermia results, 
when magnetic nanoparticles exceed a certain size, they surpass the super-paramagnetic 
limit and become magnetic; for SPIONs, that limit was reported to be 30-40 nm [39], and 
most SPIONS have a core size under 10 nm to establish sufficient thermal energy to 
allow the magnetic direction fluctuation [47]. It is therefore important to balance the 
higher tumor accessibility of smaller particles against the stronger magnetization 
potential but also the stronger aggregation potential of larger particles [52].  
Magnetic nanoparticles are excellent contrast agents for MRI as they create non-
uniform magnetic fields under externally applied magnetic fields by helping protons in 
the surrounding environment relax at a faster rate [53]. The same type of functionalized 
coatings that assist in drug delivery can be utilized to assist in stronger localization for 
imaging [54].  More recently, a technique referred to as “magnetic nanoparticle imaging” 
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emerged as a more sensitive version of MRI imaging [55], capable of real time high 
resolution 3D imaging [56]. This technique relies on the non-linear magnetization curve 
of ferromagnetic nanoparticles to reorient to a static selection field after an initial 
orientation by an applied oscillating drive field in a field-free target location. 
2.4.3 Magnetoelectric Nanoparticles (MENs) 
MENs are the latest development in magnetic nanoparticle technology, and 
include all the benefits of magnetic nanoparticles along with the benefits of the novel 
electric properties [57]. In addition to being able to respond to an applied magnetic field 
in all the same ways as conventional magnetic nanoparticles, MENs are also 
nanoconverters of magnetic fields to intrinsic electric signals due to their strong magneto-
electric coupling [58]. This non zero magneto-electric moment, in addition to the non-
zero magnetic moment that is shared with regular magnetic nanoparticles, allows another 
element of control in the drug delivery process.  
CoFe2O4–BaTiO3 core–shell MENs of ~ 30 nm size (Figure 1) have proven to be 
a successful drug delivery system [59], especially in cancer treatment  [60], [61]. Cancer 
cells have distinctive electrical properties that differ from their healthy counterparts, 
which MENs are able to interface with. As is characteristic of a rapidly proliferating 
cellular state, the membrane potential of cancer cells is comparably depolarized (i.e. less 
negative)  [62].  This depolarized membrane potential makes cancer cells more 
vulnerable to electroporation, allowing contents to be delivered inside the cell through the 
generated pores [63]. MENs serve as agents of nano-scale electroporation as they respond 
to an applied magnetic field with the generation of an electric signal, which creates a 
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nanoelectroporation effect in close vicinity to the MENs. The nanoelectroporation is 
highly preferential to cancer cells due to their electric properties: the magnetic field 
required to generate a significant interaction between the electric systems of the cell 
membrane and the MENs is orders of magnitude weaker for cancer cells than for healthy 
cells. This difference in cell membrane properties allows a very weak magnetic field to 
nanoelectroporate cancer cells but only a very strong field to nanoelectroporate healthy 
cells, allowing weak fields to be used for cancer treatment in a way that does not affect 
healthy cells. After step one of entering the cancer cells while avoiding healthy cells is 
complete, step two would be to release the drug carried on the MENs. Once the MENs 
have entered the inside of the cell, an increase in the magnetic field strength can induce 
the MENs to release the drug carried [61]. Both the directing field and higher releasing 
field are still well below the capacity to electroporate healthy cells.  A variety of 
functionalized coatings are available to fine-tune the strength of binding between the 
MENs and the desired payload drug to ensure minimal loss prior to arrival at the tumor 
site, as is directed by one magnetic field strength, and until the manually triggered 
release, as is dictated by a greater magnetic field strength [64].  
 
Figure 1. Magnetoelectric Nanoparticle Schematic 
A MEN is composed of a polar ferromagnetic metal nanoparticle core surrounded by a magnetoelectric 
coupling inducing shell. 
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The relatively weak strength required to direct MENs and induce 
nanoelectroporation at the intended destination allows regular magnets to be convenient 
options for the magnetic field generators [59]. A d.c. field can be amplified and used to 
also induce the payload release, however, low frequency a.c. magnetic fields are even 
more effective as the drug release mechanisms [61].  The generic applicability of this 
approach makes it preferable to drug release approaches relying on very specific cellular 
microenvironmental conditions at the tumor site to induce making the drug bioavailable 
upon delivery, as such conditions are more likely to differ from case to case. Likewise, 
this technique does not require the generation of heat, which could potentially damage 
surrounding healthy tissue. Furthermore, active targeting molecules can also be utilized 
to enhance MENs targeting. MENs physical targeting capabilities are complimented by 
the EPR effect, but do not necessarily require it to function, so MENs have the potential 
to target tumors too small to establish a significant EPR effect. In this scenario, cancer 
cells do not need to cluster to establish the targeting effect, as it is intrinsic to each cell in 
the form of inherent electrical properties, meaning both undetected and metastasized cells 
can be simultaneously targeted. 
2.5 Conclusion 
There are many nanoparticle treatment systems both in clinical trials and already 
being utilized in accordance with FDA regulation [65], and even more still under 
preliminary investigation with promising results. The future may hold a nanoparticle 
treatment system for every cancer, perhaps as a hybrid formulation combining multiple 
particle types carrying a cocktail of drugs for highly personalized therapy. Each 
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nanotechnology based approach has strengths and weaknesses. For example, active 
targeting usually requires a larger particle, while EPR benefits from smaller particles. 
Furthermore, EPR has been reported to be the more effective targeting agent of the two 
[66]; however, one of the weaknesses of EPR is that inflamed tissue tends to have similar 
leaky vasculature to cancer tissues, making an infection while on EPR based treatment 
more risky to the patient [39]. Similarly, organic nanoparticles degrade comparatively 
rapidly post-administration, while inorganic particles can carry a payload for an extended 
period of time; however, inorganic particles are cleared from the organism comparatively 
slower than organic particles.  
There are many aspects to consider when designing a nanomedicine for each 
cancer case, but the extensive amount of size and formulation options available is an 
asset. In any case, any nanocarrier offers extensive improvement over free drug 
treatment, as free drugs have a shorter circulation life and, therefore, need higher doses or 
prolonged administration to see the desired treatment effect. In the case of cancer, higher 
drug doses can be nearly fatal from the extensive side effects of healthy tissue receiving 
the drug. Nanotechnologies offer more accurate drug delivery or even drug free treatment 
options, along with simultaneous monitoring for vastly improved cancer patient care. We 
believe that MENs hold the greatest cancer treatment potential, as they are highly specific 
to cancer cells but also highly generalizable between different cancer types, and offer 
unprecedented opportunity for externally controlled targeting and payload release along 
with conventional nanoparticle utilities such as patient monitoring.  
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CHAPTER 3: INTRODUCTION TO MENS DRUG DELIVERY & RELEASE 
3.1 Introduction 
This chapter focuses on three previous publications from our lab group that first 
demonstrate the use of MENs in drug delivery applications. These papers represent the 
immediate predecessors to this body of dissertation research. The physics and principles 
we employ have first been described in these publications. Table 2 is a summary of this 
chapter. The work is presented in chronological order to outline the history and 
progression that lead us to the starting point of this dissertation project.  
Table 2. Preceding publications on MEN drug delivery. 
Section Paper Summary Reference 
3.2 Externally controlled on-demand release of 
anti-HIV drug using magneto-electric 
nanoparticles as carriers 
Successful drug 
delivery and release 
proof of concept 
[59] 
3.3 Magneto-electric Nanoparticles to Enable 
Field-controlled High-Specificity Drug 
Delivery to Eradicate Ovarian Cancer Cells 
Successful cancer 
treatment proof of 
concept 
[60] 
3.4 Magnetic Field-Controlled Release of 
Paclitaxel Drug from Functionalized 
Magnetoelectric Nanoparticles 
Pharmacokinetic 
quantifications and 
optimization 
[64] 
3.2 MEN HIV Drug Delivery & Release 
We first demonstrated the unique drug delivery capabilities of MENs by treating 
HIV in an in-vitro model. In this study, for the first time, we demonstrated that 
dissipation-free, energy-efficient, and low-field on-demand drug release can be achieved 
with the MEN platform; this is a great improvement upon conventional drug delivery 
platforms that lack a discrete control over the drug release portion of drug delivery. 
Figure 2 demonstrates the proposed theory of the physics behind the drug release 
mechanism that is unique to MENs. The HIV medication AZTTP is covalently and/or 
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ionically tagged onto each MEN, facilitated by the surface charge of the MENs being 
positive and the surface charge of the AZTTP being negative. Then, to release the 
medication when desired, a magnetic field is externally applied. The magnetic field 
directs a magnetic dipole moment within the MEN, which causes a strain on the bonds 
between the MEN and the payload relative to the orientation of this dipole. An alternating 
current field would repeat this process until both the forward and backward directions 
have been strained into releasing the payload. 
 
 
Figure 2. Illustration of the underlying physics of the a.c.-field-triggered release. 
A simplified (one directional) illustration of the concept of on-demand drug (AZTTP) release by MENs 
stimulated by a uniform a.c. magnetic field in X direction. (a) At zero field, only the ionic charge is present 
in the MEN shell. (b) An additional dipole moment (proportional to the magnetic field) breaks the original 
symmetry of the charge distribution in the shell. (c) As the field is increased above the threshold value 
(σionic~σME), the bond on one side is broken. (d, e) The field is reversed to break the bond on the opposite 
side of the nanoparticle. The red arrows show the electric dipole due to the ME effect. In practice, owing to 
the random configurations of nanoformulations with respect to the field, the effect is present along every 
central bond orientation. 
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This drug release mechanism is demonstrated in practice in Figure 3. AZTTP was 
mostly able to stay on the MENs at a field of 12 Oe in both a.c. and d.c. contexts. This 
ensures that ambient magnetic fields do not trigger the drug release. The difference 
between d.c. and a.c. field application on drug release is very clear around 44 Oe, where 
the d.c. field released only 16.4% of the drug, as opposed to 28.5% with a modest a.c. and 
89.3% with a strong a.c. of 1000 Hz. Interestingly, a strong enough magnetic field, d.c. or 
a.c., releases nearly 100% of the drug. This is likely due to the bond-breaking side of the 
drug chain gaining enough momentum and causing the chain to break free from the MEN 
shell even at zero frequency when the applied field is strong enough.  
  
 
Figure 3. Field strength and frequency dependence of the drug release. 
Chart showing the release efficacy of AZTTP drug bound to MENs by a remote magnetic field at different 
amplitudes and frequencies. 
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The duration of the magnetic field exposure also determines how much of the 
payload is released from the MENs, as seen in Figure 4. The exact percentages are 
presented in Table 3. With a strong enough field, the drug release is essentially 
instantaneous, whereas a weak field or intermediate field allows for a slower, timed 
release. The ability to control how much of the payload is released and when allows for a 
fine-tuning of the treatment; users can opt for an instantaneous burst release or a slow and 
steady release for a gradual increase or even maintaining a constant bioavailability to 
match the rate at which the drug is utilized by the system. There are certainly more field 
strength/frequency/duration combinations that can utilized to achieve almost any drug 
release profile with appropriately calculated doses. 
 
 
 
Figure 4. Magnetic field strength and frequency over time determines payload release 
Pharmacokinetics study results as a three-dimensional chart representation of the drug release percentage at 
various combinations of the field strength (12, 44, and 66 Oe), the frequency (0, 100, and 1000 Hz) and the 
treatment duration (1, 5, 10, 60, and 120 min). 
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Table 3. Quantification of MENs drug release in a magnetic field over time. 
 
Finally, the drug delivery platform must be confirmed to be effective in practice. 
In this demonstrative study, the MENs are used to deliver intact AZTTP past an in-vitro 
model blood brain barrier (BBB) to HIV infected brain cells. In order for a drug delivery 
system to be effective, the carrier must not damage or otherwise alter the payload. Figure 
5 shows atomic force scanning probe microscopy images of the MENs and the AZTTP 
individually, bound together, and after magnetic field triggered separation. The 
nanoformulation did not alter the carried drug, which is further confirmed by the in-vitro 
study treating active HIV in human peripheral blood mononuclear cells (PBMCs) shown 
in Figure 6. Initially, a cell viability assay confirmed negligible toxicity from the MENs 
themselves, then, in this BBB model infected with HIV, the nanoformulation was 
confirmed to be a highly effective drug delivery system.  
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Figure 5. AFM of MENs & Payload Stages 
AFM images at different stages of the release process:  
(a) MENs and (b) AZTTP chains before the loading (binding) 
step, (c) AZTTP–MEN nanoformulations after the loading 
process, (d) MENs and (e) AZTTP after the drug release by a 
44 Oe a.c. field at 1,00 Hz. Scale bar, 100 nm. 
 
Figure 6. HIV Treatment 
P24 demonstrating that the on-
demand release does not affect the 
inhibition efficacy of the drug 
(AZTTP). The p24 concentration is 
in units of pg/ml. 
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3.3 MEN Ovarian Cancer Drug Delivery & Release 
 This was the first study to demonstrate the efficacy of MENs as a cancer 
treatment. The HIV study previously discussed had successfully demonstrated the drug 
loading and release capabilities of MENs, but this study applied that drug delivery 
principle specifically to cancer. For this study, we selected the lethal epithelial ovarian 
cancer as the prototypical cancer model (in the form of the SKOV-3 cell line) due to the 
well-known challenges associated with treating this particular cancer in a clinical setting. 
The gold standard in ovarian cancer treatment is cyto-reductive surgery followed by 
paclitaxel (PTX), a mitotic inhibitor (this class of drugs is explained in Chapter 2.2.1), 
combination chemotherapy. Our nanoformulation addresses the limited specificity of 
drug uptake by the cancer that challenges the gold standard treatment. In this set of 
experiments, the PTX used is Flutax-2, a fluorescently tagged PTX that allows florescent 
tracking of the movement of the drug. Furthermore, we compare the efficacy of the newer 
MENs against conventional magnetic nanoparticles (MNs). MNs (discussed in Chapter 
2.4.2) serve as a control for the function of the magnetic aspects of the nanoparticles 
versus the magneto-electric properties unique to MENs. Additionally, we coat the MENs 
in a thin layer of glycerol mono-oleate (GMO) to achieve a specific functionalization 
(discussed in detail in Chapter 3.4). Finally, it is important to note that the principles 
demonstrated in this study are not limited to ovarian cancer; the physics-based nature of 
the MEN cancer treatment approach means that it will be applicable to almost any cancer. 
As introduced in Chapter 2.4, MENs are able to interface preferentially with 
cancer cells due to the difference in electric cell membrane properties between cancer 
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cells and healthy cells, as shown in figure 7. With no magnetic field applied to induce the 
dipole moment in the MENs, minimal interaction will occur with all cells (Figure 7a). 
However, once a small magnetic field is applied, the MENs respond with the generation 
of a small electric field that will induce a nanoeletroporation effect at the surface of the 
cell directly where the nanoparticle is located (Figure 7b). Once internalized, or at least 
preferentially located at the vicinity of cancer cells, the applied magnetic field can be 
adjusted to trigger the release of the carried payload by means of bond breakage (Figure 
7c and as shown in Chapter 3.2). 
 
 
Figure 7. Cancer Nanoelectroportation. 
Hypothesis illustration: MENs as field-controlled nanoelectroporation sites to let the drug through the 
cancer cell membranes. (a) When no magnetic field is applied, there is minimal interaction between the 
MENs and cells. (b) Once a magnetic field larger than the threshold field required to electroporate (H th) the 
cell is applied, small pores open up at the cell surface in the immediate vicinity of the MENs by means of 
nanoelectroporation, thus allowing them entry. (c) When the applied magnetic field is increased to above 
the nanformualtion release threshold (Hr), the MENs release the carried PTX into the cancer cell.  
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The first question that must be addressed is whether the MENs nanoformulation is 
significantly more effective than free-drug uptake and than conventional MN 
nanoformulation uptake by cancer cells, and Figure 8 shows MENs platform surpassing 
the other treatments. The MN-PTX nanoformulation as well as the MEN 
nanoformulations, but with the absence of a magnetic field to stimulate the release, 
performed no better than free-drug application, as expected. This is because the 
conventional MNs lack the electroporation effect of the MENs and are therefore unable 
to readily enter the cells. On the other hand, the MENs formulation holds on to the drug 
tightly prior to the externally triggered release, as per design (Figure 9 and Table 4). This 
is clearly demonstrated by the high uptake of the drug when a field is applied to the 
MENs nanoformulation. Compared to an antibody-based targeted delivery (a popular 
approach), which shows some improvement over free-drug administration, the MENs 
stimulated by a magnetic field increased the uptake by a factor of 5 (Figure 8).  
 
Figure 8. Free drug vs MN vs MEN formulation uptake by cancer cells. 
Minimal drug made it inside the cell with the free-drug, MN formulation, and MENs formulation in the 
absence of a magnetic field. The MENs in a magnetic field showed the highest drug delivery percentage, 
surpassing an antibody targeted MEN formulation by a factor of 5. 
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 Figure 9. GMO-MENs Release Kinetics. 
(a)  Chart showing the release efficacy of PTX bound to GMO-coated MENs by a remote magnetic field at 
different amplitudes and frequencies.  (b) Three-dimensional chart representation of the drug release 
percentage at various combinations of the field strength (12, 44, and 66 Oe), the frequency (0, 100, and 
1000 Hz) and the treatment duration (1, 5, 10, 60, and 120 min). 
 
Table 4. Quantification of GMO-MENs drug release in a magnetic field over time. 
 
After it was established that the SKOV-3 cancer cells readily localize the GMO-
MENs-PTX nanoformulation, we compared how the healthy counterpart to these cells, 
human ovarian microvascular endothelial cells (HOMEC), responded to the same 
treatment. As expected, because of the intrinsic differences in the cell membrane 
electrical properties, the healthy cells did not take up the treatment (Figure 10). A 
magnetic field of 30 Oe is enough to deliver large amounts of PTX into the cancer cells, 
but not enough to get a significant amount of the drug into healthy cells. 
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Figure 10. Field dependence of the drug uptake by SKOV-3 and HOMEC cells. 
(top) Quantification and comparison of drug uptake between cancerous and healthy ovarian tissue in 
different magnetic fields. (bottom) Fluorescent microscopy images demonstrating differences in uptake. (a 
and e) Free drug is minimally taken up, with the cancer cells being more prone to uptake the mitotic 
inhibitor due to faster mitosis. (b and c) Some uptake is seen with a field applied, increasing with the field, 
as expected. (d) The critical field at which drug uptake goes up significantly in the cancer cells in around 
30 Oe. (f-h) Since the nanoformulation is preventing the drug from being bioavailable and the 
electroporation threshold for the healthy cells is not in this order of magnitude, essentially no uptake is 
observed. 
Finally, the actual viability of the cancer cells and healthy cells must be observed 
under this treatment versus control treatments. Figure 11 demonstrates that the GMO-
MENs-PTX formulation under a magnetic field is extensively more cytotoxic than 
control formulations. Free drug and HER-2 antibody guided GMO-MENs-PTX (instead 
of magnetic field guided) treatments show some efficacy, but not nearly as much as the 
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magnetic field exposed MENs (Figure 11a). Furthermore, it is also clear that the 
cytotoxicity is specifically from the PTX and not from the nanocarrier because cells were 
fully viable in all of the PTX-free controls (Figure 11b).  Table 5 shows the tryptan-blue 
cell viability assay quantification of the treatments visualized by the confocal microscopy 
in Figure 11. 
  
Figure 11. Confocal imaging of SKOV-3 cell viability after treatment by different drug-carrier 
combinations with and without field. 
(a) An applied magnetic field is required to successfully treat the cancer cells, as treatment by free PTX and 
PTX loaded onto GMO-MENs directed by HER-2 antibodies achieve only minimal cytotoxicity. (b) No 
significant toxicity can be seen in the PTX-free controls. 
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Table 5. Trypan-Blue cell viability assay for nanoformulations and controls. 
 
3.4. MENs Drug Delivery & Release Optimization 
 This study describes the optimization process that our MENs underwent to 
establish the ideal functionalization and applied field settings to achieve near perfect 
delivery and release capabilities.  
Most nanoparticles have the capacity to be surrounded by a different material than 
they are composed of to establish new properties at the particle’s surface. These 
properties determine attributes like drug loading, transportation throughout the biological 
system, and drug release. Some of the most common surface modifying molecules 
include the small natural homopolymer poly-L-lysine polysorbate surfactant Tween-20, 
non-ionic oil soluble/dispersible type surfactant GMO, and the water-soluble ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC). PLGA is another option, and it can also be 
used as the exclusive component of the nanoparticle (Chapter 2.3). The type of surface 
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modification used would depend on the desired profile of drug binding and release 
kinetics.  
Previously, drug release from nanocarriers has depended on subtle changes in the 
microenvironment of the destination tissue, such as cleavage by site-specific enzymes, 
temperature changes, pH changes, redox reaction established microenvironements, etc. 
Now that MENs have opened the door to externally controlled on-demand drug release 
with the application of magnetic fields, as demonstrated in the two previously described 
studies, the exact drug-release profile can be further tailored to each medical scenario 
with surface modification. For instance, if the nanoformulation is destined for a deep 
tissue that might require an extended period of time for the nanoformulation to 
accumulate there, EDC would be a good choice for the intermediate layer. The 
carbodiimide cross-linker intermediate layer would establish a strong covalent bond with 
the payload drug by reacting with multiple amide and hydroxyl functional groups. In 
contrast, if a nanoformulation needs to achieve a nearly 100% release rate and with a 
comparatively weaker magnetic field, Tween-20 and GMO are the better options for the 
intermediate layer. These non-ionic surfactants bind their payload drugs via non-covalent 
interactions that are easier to disrupt with a magnetic field.  
The intermediate layer needs to only be approximately 2 nm thick to grant the 
functionalization properties that will determine the magnitude and frequency of the 
magnetic field needed to dissociate the payload drug from the functional layer on the 
nanoparticle. Figure 12 shows SEM images of clusters of MENs coated in GMO, Tween-
20, or EDC functional layers; these are the coatings investigated in this study to deliver a 
PTX payload. Table 6 lists the nanoparticle sizes as well as zeta potentials of the different 
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nanoformulations. Zeta potential predicts the binding affinity between nanoparticles and 
a payload, with a higher zeta potential suggesting a higher dissociation field needed to 
disrupt the higher Coulomb forces from higher effective charge on the formulation. 
Fourier transform infrared (FTIR) absorption spectrum shows the unique bonds between 
the MENs and the different coatings in Figure 13. 
 
Figure 12. SEM images of MENs with functionalized coatings 
(a) Uncoated MENs, (b) GMO-MENs, (c) Tween-20-MENs, (d) EDC-MENs. 
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Table 6. Nanoparticle size & zeta potential measurements. 
 
 
Figure 13. FTIR spectra of MENs with functionalized coatings. 
(a) Uncoated MENs, (b) GMO-MENs, as confirmed by the peaks at 1738 cm
 −1
 (ester bond) 
and 2941 cm
 −1 
(CH2 stretching modes), (c) Tween-20-MENs, as confirmed by the peaks at 1158 cm
 −1 
(C–
O ester bond) and 2862 cm
 −1
 ( C–H bond), (d) EDC-MENs, as confirmed by the peaks at 2852 cm −1  to 
2921 cm −1 (C–H alkane stretch) and 1460 cm −1 (amide bonds). 
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Aside from the payload release characteristics, the drug loading potential of each 
functional layer is also an important consideration. After incubating the drug with each 
nanoformulation, the percent loaded over time is shown in Figure 14. Likewise, the non-
stimulated release rate (decay over time) in a biological organism must be considered, 
and loss of payload in a peristaltic pump model circulatory system was calculated and 
shown in Table 7.  
 
Figure 14. PTX payload loading. 
(a) Time kinetics of PTX binding onto MENs nanoformulation surface at a 1:10 weight ratio. (b) Isotherm 
kinetics of PTX binding onto MENs nanoformulation surface at varying PTX drug concentration; readings 
taken at 3 hour of incubation time. 
 
Table 7. Intact nanoformulation in peristaltic pump human circulation model  
(8 ml/min flow for 2 hours). 
Nanoformulation Uncoated 
MENs 
GMO-MENs Tween-20-
MENs 
EDC-MENs 
Intact PTX 58.4% 79.5% 87.0% 91.1% 
 
The functional layer-determined release kinetics are shown in Figure 15. Notably, 
non-functionalized MENs most readily release their payload, with a 50 Oe field releasing 
77.9, 88.8, and 99.0% with 0, 100, and 1000 Hz, respectively. On the opposite end of the 
spectrum, 200 Oe at 1000 Hz was only able to release 6.5% of the EDC-MENs’ payload. 
GMO-MENs and Tween-20 MENs fell in-between the two extremes, with the Tween-20 
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nanoformulation requiring a substantially stronger field to release large amounts of the 
carried payload compared to GMO nanoformulation. The GMO-MENs nanoformulation 
has the advantage of a full range of release under 100 Oe, allowing a very weak magnetic 
field to release the payload fully in a short and modifiable (with exact strength and 
frequency) time span. 
 
Figure 15. Magnetic field and frequency dependent drug release kinetics from functionalized MENs. 
(a) Uncoated MENs, (b) GMO-MENs, (c) Tween-20-MENs, and (d) EDC-MENs. 
Lastly, the lack of toxicity of these functionalized nanoformulations themselves 
(as opposed to the payload they carry) must be confirmed. The results of an XTT 
cytotoxicity assay using SKOV-3 cells are shown in Figure 16. EDC does appear to cause 
minor cytotoxicity, as well as Tween-20 to a lesser extent. GMO-MENs and non-
functionalized MENs display no significant toxicity, with GMO-MENs leaving 100% of 
the cells viable after exposure. The presence or absence of a magnetic field does not 
affect the cytotoxicity results. Furthermore, the increase in field frequency consistently 
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releases a larger portion of the payload between all three functional coatings.  
 
Figure 16. Functionalized MEN XTT cytotoxicity assay. 
SKOV-3 cells are treated with different concentrations of the nanoformulations for 48 hours to determine 
any toxicity from the formulation alone. 
 
The obvious benefit to using an externally applied magnetic field to trigger 
payload release from functionalized nanoformulations is the extent of options that are 
available for drug loading and release kinetics and the control that is achieved. For 
instance, releasing 100% of the drug PTX from GMO-coated MENs requires either a 
low, 10 Oe field at 1000-Hz frequency or a d.c. (0 Hz) field of 100 Oe. This is especially 
useful in situations where a magnetic field gradient is desired to externally steer the 
nanoformulation to the target tissue, because the option to trigger payload release by 
simply increasing the frequency makes the treatment much more versatile.  
Two important concepts must be considered when utilizing an intermediate 
functional layer: (a) the field required to break the bond between the nanoparticle and the 
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intermediate layer must be greater than the bond required to break the bond between the 
intermediate layer and the payload; (b) the zeta potential, binding kinetics, and release 
kinetics are all directly related, i.e. nanoformulation with more negative zeta potentials 
will take up the payload less efficiently but will release it more readily under an external 
field, and vice versa – nanoformulations with higher zeta potentials will take up the 
payload more readily but will require a stronger field to release that payload. With these 
principles in mind, a MEN-based drug delivery system can be composed for virtually any 
drug delivery or imaging application.  
3.5 Conclusion 
 These three studies directly inspired this body of dissertation work. We wanted to 
continue with the next logical steps in testing our nanomedicine (i.e. in-vivo 
experiments), but also to address some of the critical feedback we received in response to 
these publications. For instance, the experiments detailed in Chapter 4 were developed to 
address the lack of direct confirmation that MENs have entered the cancer cells in the 
ovarian cancer in-vitro study, as this study only tracked the movement of the carried PTX 
payload.  Furthermore, armed with the knowledge that MENs offer a physics-based, 
reliable, externally controlled, targeted drug delivery and release platform that has been 
confirmed experimentally in multiple in-vitro models, this dissertation project aimed to 
demonstrate the applicability of MENs as a viable cancer treatment in a murine model. 
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CHAPTER 4: MENS USE A PHYSICAL MECHANISM TO ENTER CANCER CELLS 
4.1 Introduction 
This chapter covers some of the fundamental components of the MEN platform. 
First, the MEN synthesis process is described, followed by the functionalization and 
drug-loading process, and characterizations of the platform. Additionally, this chapter 
shows an in-vitro experiment designed to prove that the physics based approach of this 
platform allows the nanoparticles to localize inside cancer cells. In this experiment, cells 
are incubated with the MEN nanoformulation in the presence of a d.c. magnetic field, a.c. 
magnetic field, or neither. After the incubation, the cells are fully washed of any leftover 
media. Then, the cells are lysed and the internal contents of the cells are analyzed for the 
presence of MENs. For MENs to be located in the cell lysate, they must have been 
internalized with the nanoelectroporation effect caused by the magnetic field inducing the 
magneto-electric coupling intrinsic to the MENs.  
4.2. Experimental Procedures 
4.2.1. MENs Preparation  
CoFe2O4 nanoparticles were prepared by hydrothermal method:  
Core Preparation: In 15 ml of dionoized water, dissolve 0.058g of Co(NO3)2·6H20 and 
0.16g of Fe(NO3)3·9H20. Heat solution to 120 °C and add 0.2 g of polyvinylpyrrolidone 
dissolved in 5 ml of aqueous 0.9 g of sodium borohydride. Maintain solution at 120 °C 
for 12 hours to precipitate CoFe2O4 core nanoparticles.  
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Shell Preparation: The BaTiO3 precursor solution is prepared by dissolving 0.029g of 
BaCO3 and 0.1 g of citric acid in 30 ml of deionized water and by dissolving 0.048 ml 
titanium isopropoxide and 1 g of citric acid in 30 ml of ethanol. Both solutions are added 
to 0.1 g of dry CoFe2O4 core nanoparticles and the resulting solution is sonicated for at 
least two hours to fully disperse the cores in the shell precursor solution. 
CoFe2O4−BaTiO3 core−shell MENs: The sonicated mixture is dried at 60 °C for 12 hours 
with continuous stirring at 200 rpm.  The polymerized mixture is transferred to a high-
heat compatible ceramic dish. The mixture is subjected to calcination at 780 °C for 5 
hours in a CMF1100 furnace and then cooled at 52 °C/min to yield 30 nm 
CoFe2O4−BaTiO3 core−shell MENs. 
4.2.2. MENs Functionalization 
A 2 nm thick coating of GMO is deposited onto the MENs. First, 0.1 mg of GMO is 
incubated with 5 mg of MENs in 5 ml of PBS (pH 7.4) buffer for 12 h. This solution is 
gently agitated on a spinner throughout the incubation to achieve uniform surface 
modification. After incubation, the solution is centrifuged at 20,000 rpm for 20 min at 
10 °C and the supernatant discarded. To wash away any unbound GMO, the obtained 
pellet is resuspended in ethyl acetate:acetone (70:30) solution, agitated, and recentrifuged 
to discard the supernatant. This is done three times to ensure all unbound GMO is 
removed. Surface-modified MENs are lyophilized and stored at 4 °C until further use. 
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4.2.3. PTX Drug Loading 
PTX is non-covalently bonded to the GMO functional layer on the MENs.  First, 50 mg 
of PTX (dissolved in 70:30 methanol to PBS) is added to a solution of 100 ml GMO-
coated MENs (5 mg/ml concentration) suspended in 900 ml of the PBS. This nanoparticle 
and drug mixture is incubated for 3 hours on a rotator for gentle agitation. Finally, the 
solution is centrifuged at 14,000 rpm for 10 minutes at 10 °C, where any unbound PTX is 
discarded in the supernatant.   
4.2.4. TEM & EDS 
A Phillips CM-200 200 kV Transmission Electron Microscope (TEM) with Energy 
Dispersive Spectroscopy (EDS) option was used to obtain TEM images and EDS 
profiles. 
4.2.5. Magnetic Field Dependent Zeta Potential 
The magnetic field dependence of the MENs’ surface charge is measured using Malvern 
Zetasizer. To simulate the charge of MENs in the blood, 0.5 mg of MENs are suspended 
in PBS (pH 7.3, similar to human blood pH) inside a 1 ml cuvette. The cuvette is then 
exposed to an electromagnet-based uniform magnetic field ranging from 0 to +/−100 Oe 
in 10 Oe increments. The polarity of the field did not play an effect.  
4.2.6. STS Measurements of I-V Curves 
The I-V curves are obtained using the scanning tunneling spectroscopy (STS) function of 
scanning tunneling microscopy (STM) mode of Multimode. The curves are from a direct 
point contact between the STM nanoprobe and a MEN in the influence of a 200 Oe d.c. 
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magnetic field running along the central orientation. The tip distance is kept constant and 
the tunneling current (I) and voltage (V) are variable. The magnetic field is created by a 
custom multi-turn coil wrapped around the sample. 
4.2.7. Vibrating Sample Magnetometry 
A room-temperature Lakeshore vibrating sample magnetometer (VSM) with a 3-T 
magnetic field sweep was used to measure the key magnetic properties of nanoparticles 
under study. This includes the magnetization saturation and the magnetic coercivity. 
4.2.8. Fourier Transform Infrared Spectra 
FTIR absorption spectrum measurements are taken on the JASCO-4100 instrument. FTIR 
samples are prepared by placing one drop (10 μl) of the desired nanoformulation at 
concentration 1 mg/ml on a pre-cleaned silicon wafer and drying the sample overnight.  
4.2.9. Spectrophotometry 
A Cary 100 Bio UV-visible spectrophotometer at 230 nm (unless otherwise noted) is 
used to calibrate and record all PTX measurements, as described in other literature [67]. 
4.2.10. Cell Culture & Lysis 
SKOV-3 cells purchased from American Type Culture Collection (Manassas, Virginia) 
were used in these experiments. Cells are maintained in McCoy's 5A medium (Life 
Technologies, New York) supplemented with 10% fetal bovine serum (Sigma–Alrich) 
and 1% penicillin–streptomycin (ScienceCell). Cells are cultured in an incubator 
maintained at 37 °C temperature, 5% CO2, and a humidified atmosphere.  
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For the cell lysis experiment, cells are first seeded with a density of 0.7 to 1.0 × 106 cells 
in T-25 flasks and incubated overnight. Cells are allowed to reach full confluence, with 
the media being replaced every other day. At the beginning of each experiment, the 
media is discarded and replaced with 3 ml of fresh media in which the tested 
nanoformulation is suspended, and incubated under a magnetic field. Figure 17 
demonstrates the magnetic field incubation setup. The tested fields are no field, d.c. field, 
and d.c. + a.c. fields. 
After the timed magnetic field treatment are complete, the flasks are removed from the 
incubator, the media discarded, and the cells washed. The cells are then trypsinized to 
detach from the flask, washed three times in chilled PBS, resuspended in 1 ml of dimethyl 
sulfoxide (DMSO), and incubated for 1 hour at 37 °C. This way, all remnants of media 
with any leftover nanoformulation are removed before the cells are lysed with the 
DMSO. After the lysis incubation in complete, the solution is vortexed and centrifuged at 
4,500 RPM for 10 minutes in order to pellet the cellular debris. The intracellular 
components remain in the supernatant. 
The cell lysate is measured using spectrophotometry in scanning mode. A standard curve 
is generated by resuspending known concentrations of drug in DMSO and diluting it in 1 
ml of PBS for reference curves so that each peak absorbance (at a specific wavelength) 
on the curve corresponds to a known concentration of drug. It is important to note that the 
amount of drug ultimately found in the cell lysate is highly dependent on the number of 
cells in the sample. The number of cells in the sample is therefore normalized by 
measuring the protein content of that sample. This is achieved by halting the protein 
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degradation process immediately after the lysate is collected using a Bio-Rad Protein 
Assay Kit (Bradford method) followed by immediately measuring the absorbance in the 
587–591 nm range.  
 
Figure 17. Cell culture with magnetic field setup. 
A confluent flask of cancer cells is positioned directly above a magnet or electro-magnet inside the 
incubator to expose the cells to a magnetic field while maintaining ideal incubation parameters (37 °C 
temperature, 5% CO2, and a humidified atmosphere). 
4.2.11. Scanning Probe Microscopy 
A scanning probe microscope (SPM) Multimode was used to collect atomic force 
microscopy (AFM) and magnetic force microscopy (MFM) images of the 
nanoformulations in the different experimental scenarios. The images are collected with a 
CoCr-based “hard” magnetic nanoprobe in a lift mode at a scan height of 10 nm. In this 
scanning mode, each image line is scanned two times; the first scan measures the 
topography through the Van der Waals interaction (data type: height, Z range: 75 nm) and 
the second scan measures the magnetic signal through the magnetic force by lifting the 
probe at the scan height distance (data type: phase, Z range: 500). The magnetic 
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coercivity and the saturation magnetization of the MFM probe are believed to be on the 
order of 500 Oe and 500 emu/cc, respectively. 
4.3. Results 
4.3.1 The Characterization of the Physical Features of MENs 
Figure 18 summarizes the unique and defining physical features of MENs. The 
hydrothermal synthesis method described in the procedures section yields a core-shell 
structure of MENs that is clearly visible under TEM (Figure 18a); the square core without 
the surrounding perovskite shell would represent CoFe2O4 ferromagnetic nanoparticles 
(FNs). The VSM hysteresis loops for MENs and FNs of identical sizes (30 nm) 
demonstrates why FNs are utilized as a control for the effects of magnetization alone 
(Figure 18b): FNs possess approximately 40 times the saturation magnetization of MENs 
(~1 emu/g for MENs versus the ~40 1 emu/g for FNs), but no magneto-electric 
effects. The zeta potential of MENs is highly dependent on the strength magnetic field 
exposure, but not on the orientation of the applied field (Figure 18c). Since zeta potential 
characterizes the surface charge equilibrium from the double-layer chemistry of the 
particles in a liquid solution, this charge is an important consideration for cellular uptake, 
as electrically charged cell membranes would be interacting with this charge. In the case 
of MENs, the transition from no field to a field of 100 Oe (positive or negative direction 
not affecting results) increased the zeta potential by over 30%. This is an important 
component of the externally triggered payload delivery mechanism of the MEN drug 
delivery system, as the MENs will not readily interface with the electrically charged 
membranes of cells until a magnetic field is applied and the MENs’ zeta potential 
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increases. The effect an applied magnetic field has on MENs can be visualized with 
MFM imaging (Figure 18d). Here, 30 nm MENs are deposited onto a silicone oxide 
substrate and magnetized with an external field of 100 Oe. The direction of the field can 
then be seen in the image as the dipoles of the MENs are oriented directly along the field 
direction, transitioning from dark to light in the direction of the field. The conductivity of 
the MENs is shown in the STS I-V curve measurement plot (Figure 18e). A magnetic 
field of 100 Oe in either direction significantly increases the effective conductivity of the 
MENs. 
 
 Figure 18. Physical characterizations of MENs.  
(a) TEM image showing the coreshell nanostructure of MENs with the spinel CoFe2O4 core and the 
perovskite BaTiO3 shell. (b) M-H hysteresis loop of MENs, with the loop for FNs shown in the insert for 
comparison. (c) Magnetic field dependence of zeta potential for MENs in PBS buffer. (d) MFM image 
showing the dipole nature of 30 nm MENs where H is the direction of the magnetic field. (e) STS I-V curve 
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measured from a point contact between the tungsten nanoprobe of a STM setup and a MEN at three 
different field values (−100, 0, and 100 Oe), with the magnetic field applied along the central axis. 
 
These physical properties make MENs uniquely suited as nanocarriers to safely 
transport their payload through circulation while maintaining a lack of bioavailability 
until cellular internalization and payload release is triggered with an externally applied 
magnetic field on demand. 
4.3.2. The Cellular Internalization of MENs & Their Payload  
We used SPM imaging to demonstrate that MENs enter the cancer cells and 
spectrophotometry to demonstrate that the payload they carry enters with them. Flasks of 
cancer cells are treated with a MENs-PTX nanoformulation and exposed to different 
magnetic fields. The cells are fully washed of external media prior to being burst open to 
investigate the internal contents. SPM, and specifically the MFM mode of SPM, is 
selected to identify internalized MENs because their dipole nature makes them 
unmistakably recognizable in solution. Figure 19 shows a MENs only solution imaged as 
a baseline. All cellular contents lack the dark to light transition distinctive to the MENs. 
The carried payload concentration is calculated more specifically using 
spectrophotometry; the calibration parameters used are shown in Figure 20.   
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Figure 19. SPM Image of MENs only. 
The left side shows a height reading while the right side shows a phase reading of the same scan of MENs 
without any cellular contents. 
 
 
Figure 20. PTX calibration for spectrophotometer 
(a) PTX absorption maxima at a wavelength of 230 nm. (b) Standard linear calibration curve for PTX 
created for different concentrations of the drug.  
 
Figure 21 shows the field dependent nature of the MENs’ cellular internalization. 
When the cells are incubated with the nanoformulation and no magnetic field, the 
nanoformulation cannot be detected within the cell lysate. However, a d.c. magnetic field 
of 100 Oe applied to the flask during the nanoformulation incubation time yielded cell 
52 
lysate full of the MENs. These results support that the nanoelectroporation effect 
described earlier relies on a magnetic field application to manifest. 
 
Figure 21. SPM showing MENs only in field exposed cells. 
AFM and MFM processing of the same scan show that no MENs are present intracellularly in the absence 
of a field (top) but are clearly present post exposure to a 100 Oe d.c. field (bottom). 
 
Figure 22 shows that the carried payload, in this case PTX, was also internalized 
on the MEN nanocarrier.  Very little bioavailable PTX can be detected in the cell lysate 
when only a d.c. magnetic field is applied. However, this is because the drug is still 
bound to the MENs under the d.c. field needed to internalize the nanoformulation. The 
PTX can be detected in the cell lysate after the application of an a.c. magnetic field of Oe 
50 at 100 Hz. The cell lysate only then shows peaks at similar wavelengths as the 
calibrated PTX, indicating that there is free drug present in the cell lysate.  
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Figure 22. Field dependence of intracellular contents of treated cells. 
The left side of the figure shows the field dependence of MENs internalization with MFM images. The 
right shows the field dependence of the payload drug concentration intracellularly. (a) Prior to exposure, 
there are no magnetic signals in the cell contents. (b) After a d.c. field (Hdc = 100 Oe) application, the dipole 
nature of MENs (blue arrow show orientation of field) reveals them to be inside the cells (red arrows). (c) 
Spectrophotometrically measured bioactive drug amount inside the cells normalized for cell protein content 
under different a.c./d.c.-field conditions over time (shown in arbitrary absorbance units). 
 
4.4. Conclusion 
This chapter focused on detailing some of the defining physical features of MENs 
that make them a strong drug delivery system, especially in the case of cancer treatment. 
As seen in Figure 18, MENs posses both a dipole from the magneto-electric effect and an 
electric charge from the negative (non-zero) zeta potential. Both of these physical 
attributes generate electric fields which grow with the strength of the external magnetic 
field that is used to generate them. The electric field generated by the MENs’ electric 
charge (~1/r
2
) is stronger than the electric field generated from the dipole (~1/r
3
). This 
unique generation of electric fields by the MENs is exploited here for cancer 
discrimination and for loaded drug release. 
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The aim of the cell lysate experiment was to illustrate that the MEN 
nanoformulation internalizes itself into the cell, along with the carried payload. This 
experiment proved that both the MENs and the payload they carry are taken up by the 
cells in the presence of a weak magnetic field. The publication described in Chapter 3.3 
has already shown that MENs facilitate the entry of PTX into cancer cells, with high 
preference over healthy cells, in the presence of a magnetic field. However, that study 
tracked florescent PTX rather than the MENs themselves. Now it has been confirmed that 
MENs do internalize into cancer cells, as they were located using MFM inside the lysate 
of treated cells. Furthermore, the cell lysate experiments showed that the carried 
treatment is not made significantly bioavailable even inside the cell until deliberately 
released with an a.c. magnetic field (or a stronger d.c. magnetic field). This attribute will 
ensure that only negligible amounts of the drug are lost prematurely off the nanocarrier 
until essentially all of the nanoformulation has been internalized by the cancer cells. It is 
also important to note that there is little cellular internalization of the nanoformulation 
until a magnetic field is administered over the MENs. The zeta potential and conductivity 
of MENs likely has a role in this field-induced nanoelectroporation, as an applied field is 
converted into an electric output as well as an increased zeta potential by the MENs.  
It is also important to note that there was no functionalization performed on the 
MENs to make them unique to the type of cancer used in this experiment to demonstrate 
the internalization process. The mechanism of cellular entry is entirely physical in nature. 
The physics-based approach used by the MENs to gain access to the internal portion of 
cancer cells is highly advantageous from a diversification standpoint, as practically any 
type of cancer can be treated using nearly identical formulations. Other types of 
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nanoformulations or other drug delivery platforms rely on targeting molecules, such as 
antibodies, to draw the treatment to the cancer cells. The magneto-electric coupling of 
MENs pulls the MENs directly towards the cellular membrane of cancer cells, 
preferentially due to the differing electric cell membrane properties, when that coupling 
is induced by an applied magnetic field. Furthermore, additional targeting molecules can 
also be loaded onto the MENs as needed to further tailor and strengthen the individual 
treatment platform. 
The separation of the functions of nanoformulation internalization (using a weak 
d.c. magnetic field) and payload release (using a stronger or a.c. field) allows for three 
discreet steps in the drug delivery treatment process to be performed as needed: (1) initial 
administration, (2) targeting assistance/guidance, and (3) payload release. Since these 
steps are externally controllable, the optimal amount of time can be waited before 
proceeding from one step to the next. This allows for an unprecedented amount of control 
in the treatment process.  
Together with the publications described in Chapter 3, these experiments have 
established the exact trajectory of the nanoformulation when used to treat cancer cells 
under different magnetic fields. The MENs platform reliably delivers PTX to ovarian 
cancer cells in-vitro. This body of evidence supports that this nanomedicine platform will 
work to successfully treat cancer in an in-vivo model, and it resulted in IACUC approval 
for the animal studies presented in the next chapter.  
56 
CHAPTER 5: MENS EFFECTIVELY CURE CANCER IN A MOUSE MODEL 
5.1 Introduction 
 This chapter describes the first instance of MENs curing cancer in an animal 
model. We continued working with SKOV-3 human ovarian carcinoma cells in order to 
maintain consistency with the previous studies described in Chapters 3.3, 3.4, and 4, and 
to establish that this particularly aggressive cancer type can be successfully treated with a 
MEN-based nanoformulation in-vivo. We established a humanized mouse model of 
human ovarian cancer by implanting SKOV-3 carcinoma into immunocompromised 
mice. Once a visible tumor has formed, a weekly PTX-nanoformulation treatment starts 
and continues until an endpoint is reached (i.e., the tumor grows too large or the cancer 
has been cured). In addition to the main goal of demonstrating that our MEN drug 
delivery platform can cure cancer in the mouse model, we investigated four additional 
aspects of the treatment for optimization of the treatment: 
1. We compare two nanoformulation delivery methods: localized injection and 
systemic injection. A localized injection, where the treatment is injected in very 
close proximity to the tumor and flushes the tumor in the medicine, versus a 
systemic injection, where the treatment is injected into a vein and carried through 
the bloodstream, offer different benefits. A localized injection offers immediate 
access to the treatment without any travel through the periphery, however only the 
peripheral cells of the tumor get the maximum contact. A systemic injection will 
have to travel through the entirety of the vasculature until it reaches the tumor, 
however, every cell inside the tumor maintained by perfusion will ultimately be 
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exposed to the treatment. 
2. We compare the MEN cancer treatment platform to two other nanoparticle drug 
delivery platforms: MN and PLGA nanoparticle based platforms. MNs control for 
the magneto-electric coupling that is unique to MENs, as MNs are highly 
magnetic (in fact, MNs have stronger magnetic properties compared to MENs) 
but have no electric properties. PLGA nanoparticles, a fully organic particle, 
represent an FDA approved nanoparticle cancer treatment platform that controls 
for the magnetic aspects of both MENs and MNs [68]. It also allows us to 
compare our new treatment to a treatment currently on the market and being 
utilized in modern medicine. 
3. Peripheral targeting molecules in the form of Human Epidermal Growth Factor 
Receptor 2 (HER-2) antibodies and sphingosylphosphorylcholine (SPC) ligands 
are tested on the nanoformulations to determine if they improve the cancer 
targeting capabilities of the nanoformulation. Both of these molecules are over 
expressed on the surface of human ovarian cancer cells, making them good 
candidates for active targeting molecules. HER-2 [69] was extensively 
investigated in our previous in-vitro study [60], and SPC was selected as an 
alternative targeting molecule candidate [70]. 
4. Different sizes of MENs are tested as the nanocarriers for PTX. All prior 
experiments (Chapters 3 and 4) were performed with 30 nm sized MENs. More 
recently, we developed procedures for synthesizing MENs of different size 
ranges. Different sized particles offer unique combinations of surface area and 
magnetic and electric properties. 
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Furthermore, the previously described effects of d.c. and a.c. magnetic fields are 
investigated in the context of an in-vivo model.  
5.2 Experimental Procedures 
5.2.1. MEN & MN Preparation and Drug Loading 
MENs are synthesized using the hydrothermal method, coated with a 2 nm layer of 
GMO, and loaded with PTX as described in Chapter 4.2.  
The MNs used are the same component used in the ferromagnetic core component of the 
MENs, i.e. MENs sans their perovskite shell. Therefore, MNs preparation consisted of 
the cobalt ferrite precipitation protocol follow immediately by GMO coating and PTX 
loading. The properties of the base FN cores are shown in Chapter 4.3. 
To control the size of the nanoparticles synthesized, the heat parameters of the furnace 
are adjusted. By adjusting the temperature and timing of the warm up and cool down 
phase, we were able to synthesize larger nanoparticles (~100 nm) and smaller 
nanoparticles (~10 nm) than our original MENs nanoformulation (~30 nm). 
5.2.2. PLGA Nanoparticle Preparation 
PLGA nanoparticles are synthesized by the emulsion solvent evaporation method [71]. 
An important distinction is that this is an organic nanoparticle that encapsulates the 
payload rather than carrying it on the surface like inorganic nanoparticles tend to. Thus, 
the PTX is incorporated directly into the formulation of the particle. Briefly, 10 ml of the 
organic phase (consisting of 100 mg of PLGA, MW 5000, 5 mg of PTX, and 50 μl of 
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triethyl-amine in 10 ml of dicloromethane) is added to 20 ml of aqueous the phase (3% 
PVA). The saturated organic and aqueous phases are emulsified in a sonicator for 10 
minutes. The formed PLGA nanoparticles are separated from the solution via 
centrifugation of the evaporated solvent at 20,000 rpm. The resulting nanoparticles are re-
suspended in 2 ml of PBS (pH 7.4) for further use. PLGA particles are used as is, and are 
not treated with GMO or any other functional layer. 
 
Figure 23. PLGA nanoparticle imaged with AFM. 
These organic polymer nanoparticles encapsulating PTX are approximately 200 nm in size. 
 
5.2.3. Antibody & Ligand Tagging 
The procedure for affixing the HER-2 antibodies and SPC ligands to the MENs, MNs, 
and PLGA particles was adapted from Kockbek et al. [72]. In the case of MENs and 
MNs, where both the targeting molecule and PTX are carried on the surface, these steps 
were performed after GMO functionalization and prior to the PTX drug loading (in the 
case of PLGA particles, where the PTX is encapsulated during the synthesis of the 
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particle, these steps were prepared last). This technique of layering the targeting molecule 
underneath the PTX payload for the inorganic nanoparticles was quantified and 
confirmed in our previous study [60]. 
Briefly, 25 μl of N-(3-Dimethylaminopropyl)-N′-ethyl-carbodiimide hydrochloride 
(EDC) and 25 μl of N-hydroxysuccinimide (NHS), both at 1 mg/ml concentration in 
PBS, were added to 1 mg of the nanoformulation is suspended in 500 μl of PBS. The 
solution was allowed to incubate for four hours at room temperature with gentle stirring. 
After the incubation, the solution was centrifuged at 14,000 rpm for 10 minutes in a 
centrifuge maintained at 10 °C. The resulting pellet was washed three times with 1 ml of 
the PBS to remove any unbound EDC and NHS. Then, the pellet was resuspended in 300 
μl PBS and 10 μl of the antibodies or ligand (1 mg/ml) are added.  The solution was 
incubated overnight at 4 °C, with gentle stirring during the first two hours of incubation. 
The final solution was centrifuged at 14,000 rpm for 10 minutes at 10 °C and the pellet 
was washed thrice with 1 ml of the PBS. 
5.2.4. General Animal Care 
The mice used are of the SCID and Nude varieties, both purchased from Taconic. Mice 
were maintained under in the institutional animal care facility under a specific pathogen-
free environment. The mice were housed in a climate control and day/night light cycle 
control maintained room. The veterinarian-approved guide for best animal practices in 
cancer research was followed [73]. Mice were kept in groups of 2-5 (larger groups 
preferred, with smaller groups used for uneven numbers) in solid floor caging with 
bedding, and provided with a plastic igloo shelter, enrichment nestlets, and free access to 
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commercial mouse chow (global diet by Envigo) and water. Mice were carefully 
observed for general good health and well-being, as is characterized by well-groomed fur, 
clear eyes, strong appetite, enthusiastic nest-building, curiosity/investigative behavior, 
and other normal behaviors and physical traits. The weight of the mice was also 
monitored for any changes. Mouse identification was maintained with tail markings that 
were regularly reapplied as needed. 
5.2.5. SKOV-3 Xenograft 
SKOV-3 cells purchased from American Type Culture Collection (Manassas, Virginia) 
were used in these experiments. Cells are cultured in an incubator maintained at 37 °C 
temperature, 5% CO2, and a humidified atmosphere and maintained in McCoy's 5A 
medium (Life Technologies, New York) supplemented with 10% fetal bovine serum 
(Sigma–Alrich) and 1% penicillin–streptomycin (Science-Cell). Once confluent, the cells 
were washed once with PBS buffer, detached by means of trypsinazation for 2 minutes, 
neutralized using trypsin neutralizing solution, and then centrifuged at 1500 rpm for 5 
minutes to precipitate the floating cells. The precipitated cells were resuspended in 100 μl 
fresh McCoy’s 5A medium; the density of the solution was ~1 × 107 cells. This solution 
was injected into the right, outer back thigh of the mouse. The injection was performed 
on 8 week old mice under isoflurane anesthesia.  
5.2.6. Mouse Treatment  
No treatment was started until a tumor developed to a size of approximately 200 mm
3
, 
which could take up to 6 months. Therefore, treatment started on a rolling basis 
depending on when each mouse developed a large enough tumor to begin treatment. The 
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tumor size was measured by a digital slide caliper and the tumor volume was calculated 
according to the following formula: volume = width
2
 × length/2.  
Each mouse was randomly assigned a treatment group. Once a tumor of at least 200 mm
3 
developed, treatment was administered weekly until an endpoint for the mouse had been 
reached. The defined end points were: a) the mouse maintained a lack of visible or 
palpable tumor; b) the tumor exceeded 2000 mm
3
; c) the tumor exhibited breakage or 
necrosis; d) the mouse appeared to be in distress or poor health. 
The weekly treatments consisted of a fixed amount of PTX (15 μg) carried by the 
appropriate amount of the nanoformulation being tested. Therefore, the amount of 
nanoparticles used varied between the nanocarrier types to adjust for different binding 
efficiencies/encapsulation rates and ensure that an identical amount of the payload makes 
up the treatment. Each test group had a positive control trial (no treatment) and additional 
controls consised of free-PTX (no nanocarrier, simply suspended in PBS) and non-drug-
loaded nanocarriers. Each treatment formulation was suspended in 20 μl for injection. 
The treatments were injected either subcutaneously or by intra venous (IV) injection. 
Both methods utilized isoflurane anesthesia and 39 gauge hypodermic needles. 
Subcutaneous injection was performed in the immediate vicinity of the tumor, but with 
no contact being made with the tumor mass. IV injection was performed on the lateral tail 
vein (alternating sides every week to allow time for healing). Mice were kept warm under 
anesthesia using an infrared (IR) bulb heat lamp, which also helped dilate the lateral tail 
vein for IV injection. 
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5.2.7. Magnetic Field Setup 
To safely establish the d.c. magnetic fields required to influence the inorganic 
nanoformulations in close vicinity to the tumor site, a small, high magnetic moment 
neodymium magnetic coin was affixed on top of the tumor site using 3M
TM
Vetbond
TM 
adhesive. The coin was shed without any assistance in approximately one hour and was 
collected from the cage. This neodinium magnet is defined by a magnetic anisotropy 
normal to the plane, a saturation magnetization of 800 emu/cc, and the generation of a 
d.c. field on the order of 100 Oe a few millimeters away from the surface. Therefore, the 
effect of the magnet was equivalent to application of a local 100-Oe external d.c. 
magnetic field immediately after each weekly administration of PTX-loaded MENs. 
Figure 24 shows a mouse with the Vetbond attached magnetic coin. 
An a.c. magnetic field was established using a custom made cage setup shown in Figure 
25. Here, an a.c. field of 50 Oe at 100 Hz was generated immediately under the floor of a 
cage where a set of 4 electromagnetic coils was connected to two generators. Twenty-
four hours after the mouse had been treated with the nanoformulation, it is placed in a 
different cage that is then placed on this setup for the duration of a.c. field exposure 
period of 1 hour.  
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Figure 24. In-vivo d.c. field setup. 
A d.c. field is generated directly at the site of the tumor by 
affixing a magnetic disk using Vetbond, a veterinary grade 
fixative.  
 
 
 
 
 
 
  
 
Figure 25. In-vivo a.c. field setup. 
An a.c. field is generated directly under the floor of a cage to 
create a safe and comfortable environment for the mouse for 
the duration of the a.c. exposure portion of treatment. 
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5.2.8. Tissue Preparation & Imaging 
When an endpoint had been reached, the mice were euthanized by means of CO2 
inhalation followed by cervical dislocation. The tissues of interest (tumor, liver, lungs, 
kidneys, and spleen) were excised and stored in a 10% formalin solution overnight at 
room temperature.  
The tissues were processed using a VIP E 300 Tissue Tek Tissue processor SN 48940652 
to create fixed, dehydrated, and cleaned cassettes. The tissues were transferred to warm 
paraffin filled molds using warm forceps and allowed to cool until the paraffin was solid. 
A Leica 2125 microtome as then used to cut 4-μm sections, which were flattened by 
floating in a 40 °C water bath before being placed on VWR® Superfrost® Plus 
microscope slides to dry.  
For optical imaging, cover-slips were added using Tissue Tek SCA Automated 
Coverslipper at this point, or after hematoxylin and eosin (H&E) staining using standard 
procedure, e.g. using the MMI H&E Staining Kit Plus. The sectioned tissue slides were 
imaged using Leica light microscope at 40X magnification. 
5.2.9. Infrared Imaging  
IR imaging was performed on both live animals for in-vivo tumor progression monitoring 
and for immunostaining of sectioned tissues to confirm the presence of the SKOV-3 cells. 
We used the HER2Sense 645 system from PerkinElmer.  This fluorescent agent has an 
excitation and emission maxima of 643 and 661 nm, respectively, and is safe for live 
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animal use. Each dose of the agent was supplied with a solution of 100 μL of 0.02 M 
histidine, 0.02 M NaCl, 5% sucrose (pH 6.0). 
For live mouse monitoring, the HER2Sense was administrated through IV injections in 
the lateral tail vein approximately 10 hours before an imaging session to maximize the 
imaging signal. For tissue immunostaining, the slides (prepared identically to those for 
H&E staining) were incubated with the HER2Sense solution for 15 minutes at room 
temperature. Following incubation, the tissues were washed three times using PBS and 
mounted with ProLong-Gold anti-fade reagent. A Leica fluorescent microscope with a 
Cy5 filter at 40X magnification was used for the imaging. 
5.3 Results 
5.3.1. Localized Nanoformulation Delivery 
The subcutaneous trials were the first trials performed due to the simplicity of the 
treatment.  Mice were treated once a week with their assigned formulation, and a magnet 
was affixed immediately after the peritumoral injection. Since the magnet naturally sheds 
in approximately one hour, the magnet was reaffixed daily to re-magnetize the 
nanoformulations for the duration of the treatment. 
As shown in Figure 26, positive controls were established in the form of (a) no 
treatment; (b) initial treatment that is then halted (three treatments are administered 
before cessation); (c) MENs without any attached PTX; (d) free PTX without any 
nanocarrier. We saw a notable reduction in tumor growth rate when mice were treated 
with the GMO-coated MEN nanocarrier loaded with the PTX payload. In this trial, four 
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mice were treated with an identical nanoformulation. Control mice that receive no 
treatment reached an endpoint in fewer than 10 days, and mice that received free-drug or 
only the nanocarrier reached an endpoint in just over 20 days. By direct comparison, as 
shown in Figure 27, all the mice undergoing the MENs-PTX treatment were doing well 
and maintaining controllable tumors between ~100 mm
3
 and ~700 mm
3
 at day 20 in their 
treatment. The entire progression of the MENs-PTX treatment is shown in Figure 28. All 
the mice that underwent MENs-PTX treatment performed much better than control mice, 
and were able to maintain a treatable level of the cancer for up to twice as long as control 
mice before reaching an endpoint. However, none of the mice were able to be fully cured 
using a peritumoral subcutaneous injection delivery method for the nanoformulation. For 
this reason, all further experiments were performed using the IV delivery approach. 
 
 
Figure 26. Positive controls. 
References for the efficacy of the nanoformulation tested were first established by observing mice with no 
treatment, halted treatment, nanocarrier not loaded with the drug, and free drug. 
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Figure 27. Early MENs-PTX treatment trials. 
The first 20 days of the MENs-PTX nanoformulation treatment are shown with identical scaling to 
establish a direct comparison to positive control mice. 
 
 
Figure 28. Full MENs-PTX treatment trials. 
The full duration of the MENs-PTX nanoformulation trials are shown here. Mice on this treatment were 
able to maintain good health long after control mice had reached an endpoint. 
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5.3.2. Comparisons of Nanoparticle Delivery Systems 
 This set of trials aimed to compare the efficacy of MENs versus conventional 
MNs and organic PLGA particles, as well as to determine to what extent each of these 
platforms benefited from active targeting molecules. These experiments utilized the IV 
injection delivery routes for the nanoformulations. While both PLGA nanoparticles and 
MNs showed a reduction in tumor development speed, MENs treated subjects showed the 
best outcomes, including a full eradication of the cancer.  
 Figure 29 plots the progress of the control groups (a), the MENs experimental 
treatment groups (b), and the PLGA references groups (c), respectively, all with identical 
scaling for a direct comparison. Figure 29a shows the most relevant controls to the MENs 
treatment platform in the form of the positive controls for this trials, blank MN carriers 
(no PTX), and PTX-loaded MNs (two mice in each group). As expected, the untreated 
mice had the worst outcomes, followed closely by MNs lacking the active drug in the 
treatment platform. The two subjects on the MN-PTX platform demonstrated an 
improved outcome. It should be noted, however, that these subjects were started on their 
treatment at tumor sizes slightly less than the intended 200 mm
3 
due to health concerns. 
Due to the earlier introduction of the treatment, the favorable outcomes are likely to be 
slightly overestimated for this group. Figure 29b shows the MENs-PTX formulation, 
where the whole group had performed the best as compared to the other 
nanoformulations groups. All the mice treated with the MEN-PTX formulation never 
exceeded tumors volumes of more than twice the starting size (i.e. 400 mm
3
). 
Interestingly, the addition of targeting molecules did not show any notable improvement 
of treatment, as the HER-2 antibody, the SPC, and the no-targeting-molecule 
70 
formulations all performed extremely well. In fact, the mouse treated with the non-active 
targeted MENs-PTX formulation had actually performed the best out of this set; this 
specimen was fully cured of its cancer using this treatment. The efficacy of the MENs 
drug delivery platform is then compared to the already well-established PLGA platform 
(Figure 29c). As expected, PLGA was also a successful cancer treatment platform; 
however, the PLGA nanocarrier did seem to strongly rely on active targeting molecules 
to function at the highest efficacy.  Both the HER-2 antibody and the SPC ligand showed 
improved outcomes compared to non-active-targeted PLGA particles, with the HER-2 
PLGA-PTX formulation being the only other treatment type in the trial (other than the 
MENs-PTX formulations) to reduce the tumor size as opposed to simply slowing down 
growth. 
a)  
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b)  
 c)  
Figure 29. Efficacy of different nanocarrier platforms delivered via IV on tumor volume. 
a) Untreated tumor growth, blank MN carrier, and PTX loaded MN carrier. b) The MENs-PTX cancer 
treatment platform, as well as further active targeting with HER-2 and SPC. c) The PLGA-PTX cancer 
treatment platform, as well as further active targeting with HER-2 and SPC. 
 
5.3.3. Size and A.C. Field Optimizations of the MENs Treatment  
 After establishing that the MENs-PTX platform can effectively treat the cancer, 
we wanted to investigate if minor changes to the platform offer improved outcomes. 
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Specifically, the original trials relied on stimulating the magneto-electric coupling of the 
MENs with soley a d.c. magnetic field (in the form of the neodymium magntic disk) in 
order to maintain the simplest form of the treatment for a direct comparison with the 
currently utlized PLGA-nanoformulation-based treatments, which offer no reliable 
externally triggered release mechanisms. Furthermore, we were later able to develop a 
range of sizes for MENs, so we also had the opportunity to investigate if a difference in 
particle size offered any notable advantages to cancer treatment.  
 The orgininal MENs were developed to be approximately 30 nm in size. 
Therefore, we tested MENs that were approximately three times smaller (~10 nm) and 
three times larger (~100 nm) than the orignial particles. Interstingly, the 10 nm MENs 
were too small to establish as strong of a magneto-electic effect as the larger particle 
sizes, likely due to the amount of surface area versus volume required to do so. For this 
reason, the 10 nm MENs exhibited properties somewhere inbetween MNs and MENs, 
making them an excellent control for particles of identical chemical composition and 
synthesis technique to MENs, but that display the physical magnetic properties more 
closely to those of MNs. When injected via IV and activated with the externally affixed 
magnet, both the 10 nm and 100 nm MENs performed acceptably as cancer treatment 
platforms, as shown in Figure 30; however, the previous trials using 30 nm MENs were 
still the most successful. 
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Figure 30. MENs size variants. 
Compared to the 30 nm MENs used in pervious trials, a 10 nm and 100 nm variant are tested. 
 
Next, we wanted to incoroporate the manual external release of the payload drug 
from the MEN carriers as shown in the in-vitro studies (Chapters 3 & 4) in this in-vivo 
study. This was accomplished by placing the mouse’s cage into a calibrated a.c. 
electromagnetic field 24-hours after the weekly treatment was administered. The results 
are shown in Figure 31. The role of the magneto-electric coupling is especially higlighted 
in these a.c. field trials, where both the 30 nm and 100 nm MENs formulations performed 
extensively better than the 10 nm MENs. Since the 10 nm MENs lack a strong magneto-
electric effect, they were not activated any further by the applied a.c. field to release their 
carried payload, thus an externally triggered payload release was unable to be established 
and the payload would only be released by the passage of time. By comparison, both the 
100 nm and 30 nm MENs-PTX treatment groups extensively slowed the growth rate of 
the tumors. Again, the 30 nm sized MENs performed the best compared to the rest of the 
treatment groups. 
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Figure 31. A.C. field application to different sized MENs. 
Due to their intrinsic magneto-eclectic coupling, both the 30 nm and 100 nm MENs were able to utilize the 
a.c. field for improved treatment outcomes. 10 nm MENs were unable to do this as effectively. 
 
5.4 Conclusion 
This chapter has shown the first in-vivo demonstration of the efficacy of the 
MENs platform as a cancer treatment. When compared to conventional magnetic 
nanoparticles (MNs) and FDA approved organic polymer nanoparticles (PLGA) for 
reference, the MEN drug delivery platform for PTX was the most effective at treating the 
model cancer. While both localized and systemic injection delivery of the 
nanoformulation showed improvement, systemic introduction of the MENs-PTX 
treatment was able to fully cure all traces of the cancer in the animal model. This was 
expected, as peritumoral injections could not reach every cell in the tumor mass nor 
benefit from the EPR effect. 
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The most successful mouse trial saw the mouse cured by the 88
th
 day into the 
weekly treatment (Figure 32), where no tumor could be seen, palpated, or located 
internally with fluorescent imaging. A live-animal safe florescent tag for the HER-2 
receptor was selected to identify the presence of SKOV-3 cells, which greatly over-
express the HER-2 receptor, underneath the outer tissues (skin and fat) that may not be 
able to be seen or palpated; this was done to confirm a full eradication of the xenografted 
tumor (Figure 33). The same tag is then used in postmortem tissues examination, along 
with H&E staining, to locate any metastasized cancer (Figures 34 and 35). While 
metastasized SKOV-3 cells were confirmed in the organs of untreated positive control 
mice, no metastasized tissues we located in MENs-treated mice. This was consistent 
between H&E investigated tissues and HER2Sense investigated tissues. Good health was 
maintained by the MENs-treated mice throughout the treatment, as indicated by weight, 
physical observation, and active behavior. The cured specimen was observed for three 
months after the tumor was fully eradicated; the mouse had gained about 20% of its body 
weight (a favorable outcome) and demonstrated perfect physical health, which was 
supported by behavioral tendencies to be active, curious, and nesting.  
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Figure 32.  A fully cured mouse’s progress. 
a) The mouse is shown wearing the d.c. magnetic field generating magnet. b) The volume of the tumor at 
the start of treatment was 286 mm
3
. c) The tumor volume was 51 mm
3
 35 days into the treatment. d) The 
tumor volume was at 20 mm
3
 57 days into the treatment. e) There was no tumor remaining 88 days after the 
treatment had begun. 
 
a)  
b)  
Figure 33. HER2Sense monitoring of live animals. 
a) Tissues from an untreated mouse are shown to demonstrate that metastasis to the kidneys had occurred. 
b) Tissues from treated mice are shown to demonstrate that none of the investigate organs showed signs of 
metastasized cancer nor any changes from healthy morphology.  
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a)  
b)  
 
Figure 34. H&E stained organs. 
a) Tissues from an untreated mouse are shown to demonstrate that metastasis to the kidneys had occurred. 
b) Tissues from treated mice are shown to demonstrate that none of the investigate organs showed signs of 
metastasized cancer nor any changes from healthy morphology.  
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a)  b)  c)  
Figure 35. HER2Sense stained organs. 
a) Tumor tissue of an untreated specimen. b) Kidney tissue of an untreated specimen. c) Kidney tissue of a 
treated specimen, showing no presence of HER-2 and therefore no metastasis 
. 
Only the MENs-PTX formulations were able to reduce the tumor size enough to 
ultimately cure the cancer, although the HER-2 antibody active targeted PLGA-PTX 
particles also reduced tumor volume. The PLGA platform’s reliance on active targeting 
molecules makes it more sophisticated to formulate and less generalizable to different 
cancers. PLGA not tagged with further targeting molecules rely mostly on the passive 
EPR effect, which is why notable improvement was observed upon the introduction of a 
surface targeting molecule that enabled the platform to utilize active targeting. What may 
be occurring is that without the active targeting to speed up the tumoral localization, the 
PLGA particles had broken down and released their carried payload before reaching the 
tumor site, thereby not delivering some of the treatment to the cancer. By comparison, the 
MENs did not rely on active targeting, although they likely also benefited from it at least 
somewhat. Presumably, the forces of attraction to the electrical aspects of the cancer cell 
membrane are comparably strong to the forces of attraction of the antibody and ligand to 
their respective surface proteins.  
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The electric properties unique to MENs also enable the application of a small 
external a.c. magnetic field to be used to control the timing of the payload release from 
the MENs. While time will also eventually release a drug from a nanocarrier, the ability 
to be able to do so as soon as needed is highly beneficial for customizing individual 
treatments. Mice under a.c. magnetic field treatment following the regular treatment 
regime (nanoformulation injection + d.c. magnetic field) responded positively to the 
treatment.  Both the d.c. field and a.c. fields used in this mouse study can easily be scaled 
up for human use with strategic use of solid magnets or magnetic field generator setups. 
This study was the very first of its kind, and because of this the number of 
animals used was deliberately kept minimal. Furthermore, to meet or exceed animal 
husbandry standards, each animal was treated as indicated by its health and well-being 
above as indicated by the experiment. For this reason, some of the treatments started 
earlier than the initially defined starting point of 200 mm
3
. Additionally, animals were 
euthanized if found to be in distress, forcing some of the trials to stop earlier than desired. 
While a larger study would undeniably be ideal, this mouse study answered the most 
pressing question regarding this novel cancer treatment platform, and that was “does the 
efficacy of the MENs cancer treatment platform translate from in-vitro to in-vivo?” with a 
definitive “yes.” 
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CHAPTER 6: BIODISTRIBUTON AND CLEARANCE OF MENS 
6.1 Introduction 
 In this chapter we investigated the biodistribution and clearance of our novel 
nanoformulation, MENs, for the very first time in an animal model. We employed a new 
SEM/EDS based technique to systematically map out nanoparticles in tissues. In this 
study, we specifically compared the biodistribution of mice being treated for cancer to the 
biodistribution of mice that do not have cancer. We have found that the nanoformulation 
accumulates in the tumor preferentially, however it is also important to document where 
the MENs would travel if there are no cancer cells to selectively uptake it. This is 
especially relevant for post-treatment clearance after the course of treatment is 
completed. Also, since MENs can be used as a drug delivery platform for treatments 
other than cancer, this information is pertinent to other potential nanoformulations with 
MENs for other medical uses. To accomplish this, we compare the organs of the cancer-
treated mice from Chapter 5 to a cancer-free cohort. In order to investigate the long term 
trajectory of the MENs, the cancer-free group was further divided into three time periods: 
1 week, 1 month, and 2 months. Four different nanoparticle sizes were investigated for 
size related differences, including MENs sized at 10 nm, 30 nm, 100 nm, and also new, 
larger MENs sized at ~500 nm. This was done to establish a sort of stop-motion based 
time line showing where the particles go soon after administration, where they remain, 
and where they go en route to being cleared, as affected by the particle size.   
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6.2 Experimental Procedures 
 All the protocols remain unchanged from the experimental procedures described 
in Chapters 4 and 5 to maintain the highest level of consistency.  
6.2.1. MENs Preparation & Functionalization 
CoFe2O4 MENs were synthesized via the hydrothermal method as described in Chapter 
4.2.1 and functionalized with a 2 nm thick layer of GMO as described in Chapter 4.2.2. 
This was done identically for the 10 nm, 30 nm, 100 nm, and 500 nm MENs used. 
6.2.2. General Animal Care 
Mice were cared for as described in Chapter 5.2.4. 
6.2.3. Mouse Treatment 
Two groups of mice were used for this experiment: 
1) The mice investigated for cancer treatment in Chapter 5 were used for the cancer 
group in this study to minimize redundant animal use. Specifically, the application of 
magnetic fields was investigated as related to the trajectory of the MENs throughout the 
physiology. 
2) A group of identical mice from the same immunocompromised strain was used 
for the general biodistribution and clearance group. These mice were randomly assigned 
a nanoparticle size and clearance duration. The mice were given a single bolus lateral tail 
vein IV injection of 5 mg GMO-MENs (there was no drug conjugated to the 
nanoparticles) suspended in 200 ul sterile PBS. A high concentration was deliberately 
selected to best demonstrate the effects of the nanoparticles after a single treatment and to 
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make the data more comparable to the cancer group, which had received continuous 
weekly treatments.  
6.2.4. Tissue Collection & Preparation 
The organs excised for biodistribution and clearance studies were the liver, lungs, 
kidneys, and spleen, as these are the organs most commonly associated with inorganic 
nanoparticle accumulation [74]. The brain was also collected for examination. 
Animals were euthanized and the tissues were processed as described in Chapter 5.2.8, 
minus the addition of coverslips and the histology staining protocol. Immediately prior to 
SEM imaging, the slides were gently rinsed with PBS to remove any excess paraffin from 
the tissues and allowed to dry for improved definition. 
6.2.5. SEM Imaging with EDS Analysis 
For SEM imaging, tissue slides were gold-sputtered for 75 seconds, grounded with 
copper tape for proper conductivity, and imaged using a JEOL- JIB 4500 Multibeam 
system (FIB/SEM) with a Thermo-Scientific Noran System 7. Back-scattered electron 
detection mode was used to locate areas of high densities of heavy metals under which 
MEN clusters would fall. Then, each nanoparticle cluster candidate was investigated 
using the “point-and-shoot” mode of the energy dispersive spectroscopy (EDS) 
machinery, specifically for the elements barium (Ba) and titanium (Ti). While many 
heavy metals are naturally occurring in physiology, such as iron [75] and calcium [76], 
the MEN perovskite shell composing elements of Ba and Ti are relatively rare. Thus, 
EDS-identified Ba and Ti confirms a MEN deposition point. 
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SEM/EDS image quantification was performed using NIH developed ImageJ software 
[77]. This software calculates the percentage of the tissue area that contains MENs. 
Multiple images that are the best representatives of the biodistribution in the organ were 
selected for quantification. The images were scaled to match and the software’s 
identification threshold was manually adjusted to correctly identify the MEN clusters 
specifically in the areas of the tissues (i.e. discriminate between tissues on the slide 
versus the glass slide itself).  The quantifications were then averaged between all 
analyzed images and plotted. 
6.3 Results 
6.3.1. MEN Biodistribution and Clearance in Mice Treated for Cancer 
Using SEM imaging with EDS analysis, we are able to detect MENs inside the 
tumor tissue of MEN nanoformulation treated mice. This confirms that the MENs 
actually enter the tumor mass, past the outer tumor capsule, to deliver the treatment 
internally (rather than just washing the tumor with the treatment). Furthermore, an 
applied magnetic field amplifies this effect.  
Figure 36 shows an example of the EDS analysis on a cluster of MENs in tumor 
tissue. As seen in Figure 36b, the elements with consistent signal distribution throughout 
the whole surface were not concentrated at any one point. Silicon (Si) was 
overrepresented on areas of the slide where tissue was absent as the signal was coming 
from the glass slide itself, while Ba and Ti show MENs localized on the tissue portions 
(not on the Si heavy glass portions) of the slide. Figure 36c gives a quantitative 
comparison of all the elements present in the EDS analyzed image from Figure 36a.  
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a)  
b)  
85 
c)  
Figure 36. EDS analysis for MENs presence in tumor tissue. 
a) The backscattered view of the tumor tissue is shown on the left. On the right is the magnification used 
for EDS analysis. b) The elements EDS was used for are shown here. c) The elements EDS detects are 
quantified here. The green vertical line highlights the peak that represents Ba and Ti, as indicative of MEN 
presence. 
 
An interesting observation was that the clusters of MENs in the tumor tissue were 
not haphazard in distribution, and instead followed the contours of the tumor’s tissue 
morphology, as seen in Figure 37. For mice treated with a subcutaneous injection of the 
MENs, most of the clustering occurred towards the periphery of the tumor, as expected. 
By contrast, IV treated mice had MEN clustering throughout the entire tumor, which 
likely explains the improved efficacy of IV versus subcutaneous injection described in 
Chapters 5.3 and 5.4. This helps to demonstrate that the entry point of the MENs into the 
tumor, with the IV entry points being essentially limitless throughout the tumor while the 
subcutaneous entry points are limited to the periphery and are therefore much slower to 
reach the core of the tumor, ultimately helps determine the efficiency of tumor reduction. 
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This was consistent with the subcutaneous nanoformulation treated mice showing a 
reduction of tumor growth speed (as the treatment whittles away at the outside of the 
tumor mass) while the IV treatment works to target the tumor cells inside-out for a 
notable deterioration of the tumor mass. This concept is illustrated in Figure 38. The 
subcutaneous injection, while demonstrating a positive effect, was not able to notably 
shrink tumors because the tumor tissue furthest away from the periphery is able to 
continue growing even while the periphery is being affected by treatment. On the other 
hand, systemically administered treatment treats the whole tumor, thus mostly affecting 
the areas that are best perused and that are, therefore, the most likely to have grown the 
most robustly in the absence of the treatment. 
87 
 
a)  
b)  
Figure 37. EDS located MENs follow tumor morphology. 
a) Back-scattering mode SEM images show the tumor morphology. b) Ba and Ti confirm the identity of 
MENs in the tissue as they fit perfectly in the contours of the tumor tissue. 
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a) b)  
Figure 38. Subcutaneous vs IV localization of MENs. 
The red mass demonstrates an encapsulated tumor. The blue spheres represent the MEN treatment, with the 
yellow arrows projecting the trajectory of the treatment throughout the tumor mass. (a) While the entirety 
of the treatment is available in the immediate vicinity of the tumor, subcutaneously administered treatment 
suffers from having to internalize past the outer tumor capsule and being delayed from reaching the inner-
most cells of the tumor. (b) By contrast, IV administered treatment has an available tumor entry point 
anywhere tumor cells are vascularized. This lets the treatment enter multiple areas of the tumor 
simultaneously and begin eradicating cells throughout the entire tumor, which accomplishes an overall 
reduction of tumor mass. 
 
In addition to the nanoformulation administration method having notable 
biodistribution differences, it was also not surprising to see that the incorporation of an 
externally applied magnetic field also modified the biodistribution. The application of a 
d.c. magnetic field on the order of 100 Oe in the form of a magnetic coin affixed to the 
tumor site enhanced the localization of the MENs into the tumor preferentially over the 
peripheral organs, as shown in Figures 39 and 40. These charts are drawn from three 
representative mice under different cancer treatment conditions: (i) a fully cured mouse 
that has completed its course of MEN-PTX nanoformulation treatment and was observed 
for three months after the final treatment was administered before being euthanized for 
biodistribution studies; (ii and iii) two mice in the very early stages of treatment (two 
weekly administrations into treatment) were used as positive controls demonstrating the 
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biodistribution when the tumor was at its largest, peak value. (ii) One mouse had no 
further tumor targeting, while the other (iii) had a magnetic coin affixed to the external 
surface of the tumor to establish a magnetic field of approximately 100 Oe directly at the 
tumor site. 
In the magnetic field treated mice, a little under a third of the MENs were 
localized in the tumor. This contrasts with the non-magnetic field treated mice, which 
contained approximately a tenth of the total MENs in the tumor mass (as opposed to in 
the peripheral organs). The field treated mice overall had the majority of the MENs 
localized in the tumor tissue, while non-field exposed mice saw the majority of the MENs 
localize in the liver and lungs, followed by the spleen, and only then the tumor. The cured 
mice had no tumor to house MENs, however, these mice also had a very small fraction of 
MENs present throughout the periphery as well. This is presumably because the three 
month period after the cessation of MEN administration had allowed most of the MENs 
to clear from the mouse unassisted. Other than the strong preference for the tumor, the 
proportion of distribution throughout the peripheral organs was similar between the field 
and no-field treatment groups, as would be expected of nanoparticles of identical size and 
composition. This distribution pattern helps demonstrate the unique role of the magnetic 
field in this type of cancer treatment. 
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Figure 39. MEN distribution in cancer treated mice 
This chart shows the areal concentration of MENs in the tumor site compared to peripheral organs sites 
(liver, lung, spleen, and kidney) as affected by the MEN treatment conditions: fully cured, under treatment 
with no applied magnetic field, and under treatment with an applied magnetic field. 
 
 
Figure 40. Overall organ vs tumor MEN load in MEN treated mice. 
This chart shows a comparison between the areal concentration of MENs in the tumor versus peripheral 
organs (liver, lungs, kidneys, and spleen combined) of a mouse being treated for cancer with an applied 
magnetic field, a mouse being treated for cancer without an applied magnetic field, and a mouse that has 
been successfully treated of its cancer. 
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6.3.2. MEN Biodistribution and Clearance over Time 
Biodistribution & Clearance through the Liver, Lungs, and Spleen 
The liver, spleen, and lungs had easily locatable MEN clustering throughout all 
the tested time points. Figure 41 shows the gradual clearance of the MENs from these 
organs over time by maintaining a constant scale for reference. Figure 42 shows a close 
up comparison to help visualize the concentration of the different particle sizes in the 
organs over time.  
As seen in Figure 41, after one week following administration, most of the MENs 
were located in lung tissue, followed by the spleen, with very little found in the liver. 
This contrasts with the one month post-injection time period, where MEN (sizes 10 nm 
through 100 nm) presence had actually grown in the liver; this was the only documented 
instance in the trial where the concentration of MENs in an organ increased over time. 
What appears to be happening is that the large initial concentration of particles in the 
lungs travels to the liver by means of hepatic clearance, as indicated by the greatest 
reduction of particle concentration in the lungs and the greatest increase of particle 
concentration in the liver. The spleen had a less dramatic reduction in particle 
concentration from one week to one month post-administration. Then, at two months 
after the bolus administration, particles at all organ sites had reduced further, indicating a 
successful gradual clearance process of all the tested sizes.  
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a)  
b)  
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c)  
Figure 41. MEN clearance over time. 
The vertical axis is MEN cluster absorbance signal per tissue area. a) 1 week post injection b) 1 month post 
injection c) 2 months post injection. 
 
 Figure 42 focuses more on demonstrating the changes in the organ localizations 
between the different particle sizes, considering that in all instances the overall 
nanoparticle concentration reduced over time. The growth of MEN presence in the liver 
for 10 nm, 30 nm, and 100 nm MENs is very clear here between the one week (42a) and 
one month (42b) post-injection period. Interestingly, 500 nm MENs were not highly 
present in the liver or the spleen at one month-post injection, and remained at a high 
concentration in the lung throughout the course of observation. Overall, the 10 nm MENs 
were the least present in the studied organs at all times throughout the study (possibly 
because they were eligible for renal clearance, as discussed in the next section), and were 
likely to be the first to completely clear from the body. By contrast, the 500 nm particles 
were likely to be the slowest to clear, with the 30 nm and 100 nm falling in order to 
establish the pattern that the smallest and largest particles were fastest and slowest to 
clear, respectively. What appears to have happened was that the initial deposition of 
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MENs occurred mostly in the lungs and in the spleen; then the MENs in the spleen are 
slowly processed for biological clearance while many of the MENs in the lung 
transitioned to the liver, as well as the spleen to a lesser extent. This process then 
continues until the particles are fully cleared out of the biological system, which would 
presumably take a total of 3-4 months depending on the particle size.  
a)  
b)  
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c)  
Figure 42. MEN organ distribution over time. 
The vertical axis is MEN cluster absorbance signal per tissue area. a) one week post injection b) one month 
post injection c) two months post injection. 
 
Biodistribution & Clearance Considerations of the Kidneys 
 The presence of MENs in kidney tissue was so minimal that it was difficult to 
quantify. Very few MEN clusters could be identified, but a region positive for MEN 
clusters is shown in Figure 43.   
 
Figure 43. 10 nm MEN cluster in glomerular region of kidney. 
These SEM back-scatter images show an example of MEN clusters in the kidney. The yellow circles 
highlight the clusters. The image on the right is increased magnification into the blue box to better show the 
glomerulus. 
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The few clusters that were located in the kidneys tended to be centralized in the 
glomerular regions of the kidney tissue. This finding is not surprising considering that 
most of the literature supports that only the smallest nanoparticles, typically those that are 
under 10 nm and closer to 5 nm, are consistently cleared through the renal clearance 
pathway [78]–[80]. This is due to the glomerular capillary wall pathway for glomerular 
filtration, where the filtrate passes through the fenestrated endothelium, glomerular 
basement membrane, and finally the filtration slits [81]; these filtration slits themselves 
are approximately 43 mm wide [82], however the physiological pore size is closer to 5 
nm after the glomerular layer assembly is considered as a collective [83]. In this case, it 
can be assumed that only the smallest of the synthesized particles, which may fall slightly 
closer in size to 5 nm, are those that were found in the kidney tissue. Alternatively, any 
small imperfections in the renal complex tissue could also allow the nanoparticles to 
enter the glomerular region.  
Biodistribution & Clearance Considerations of the Brain 
 MEN clusters found in the brain tissues were very rare and very small. A fully 
comprehensive brain study can be performed at a later time to determine the exact 
biodistribution and clearance of different sized MENs through the brain, as the current 
data is more preliminary in nature. All instances of MENs found in the brain are mapped 
on the GENSAT Brain Atlas image [84] in Figure 44. The time after the initial MEN 
administration is noted in Table 8. The instances of particles discovered in this 
experiment are too sporadic to draw any meaningful conclusions, but the finding of 
different sized particles in different brain regions throughout different time points is a 
good starting point for the development of brain cancer specific nanomedicines.   
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Figure 44. Brain atlas showing located MENs. 
All the MEN clusters located in this experiment are approximately displayed on this open access atlas 
image of a mouse brain.  
Table 8. MEN clusters in brain regions over time.  
 1 Week 1 Month 2 Months 
Olfactory Bulb 
 
 
 
Cerebral Cortex 
 
  
Thalamus 
 
  
Cerebellum 
  
 
Midbrain   
 
Medulla  
  
Pons  
 
 
6.4 Conclusion 
This chapter has described the biodistribution of MENs in mice receiving cancer 
treatment, with and without applied magnetic fields, as well as the biodistribution of 
MENs through the body of healthy mice. Our findings show that our MENs demonstrate 
strong preference for tumor tissue over peripheral organs, which is further amplified by 
applying a magnetic field at the site of the tumor for further targeting the MENs into 
tumor tissue and away from healthy tissue. It is important to note that the goal of the 
experiments in this chapter was not to quickly discharge the MENs, but quite the 
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opposite: to track a large concentration of the MENs over a longer period of time for a 
more robust understanding of the biodistribution. 
Most of the MENs clustered in the liver, spleen, and lungs, as was expected for 
the size range used [79]. The lung is a very common accumulation point in mouse 
biodistribution studies for most systemically administered nanoparticles (organic and 
inorganic) due to the fact that the lung capillary bed is one of the first robustly perfused 
areas that the nanoparticles encounter after the initiation of circulation from the lateral 
tail vein IV administration point [85]. Nanoparticles larger than 200 nm are found to 
typically accumulate in the liver and spleen, where they are processed for clearance, as 
well as intermittently in the lungs, however particles smaller than 200 nm but larger than 
those filtered through the kidney also tend to follow the same trajectory but to a lesser 
extent [79]. This explains why our 500 nm MENs were preferentially concentrated in the 
lungs, even two months after injection (Figure 42c). The reason behind this size-
dependent difference in distribution can better be explained with how nanoparticles leave 
the bloodstream to enter organ tissues. Specifically, the particles in the size range used 
here would most likely rely on discontinuous endothelium for their bloodstream exit 
points [86]. The discontinuous type of endothelium is characteristically found in both the 
liver and the spleen, and has much larger pores than both continuous endothelium (lining 
most of the vasculature) and fenestrated endothelium (characteristic of kidney lining). 
This helps explain why many of the MENs were located in the organs of the 
reticuloendothelial system (RES) (i.e. liver and the spleen), where they were likely being 
processed for clearance from the body via RES clearance mechanisms. 
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An interesting consideration for the distinctive, albeit small, presence of MENs in 
the kidney tissue of the cancer mouse group (Figure 39) is that metastasis of SKOV-3 
cells into kidney tissue was confirmed in the H&E staining and HER-2 fluorescent 
imaging histological studies discussed in Chapter 5 for those animals. The cancer-free 
biodistribution group having even less identifiable MENs in the kidneys further supports 
the notion that the MENs were drawn to cancer cells that had metastasized into the 
kidneys for a slightly stronger presence than in the kidneys of cancer-free mice. 
While the brain localization of MENs is still in the preliminary stage regarding 
the course of localization over time and of the differently sized MENs, we did expect to 
see MENs present in brain tissue as is documented in this study. This is especially good 
news for the applicability of MEN based cancer treatment for brain cancers, a particularly 
challenging cancer type to treat [87]. Likewise, other treatments for brain-related 
disorders, such as Alzheimer’s or Parkinson’s, can be fullfulled with MENs as 
demonstrated in our previous publication [6]; in this previous study, we utilized 
systemically administered nanoparticles to stimulate the brain with the application of an 
external magnetic field. The current biodistribution study shows that small amounts of 
MENs are able to localize into the brain without the assistance of an applied magnetic 
field. A more elaborate study that shows the exact time, size, and brain region 
relationships in the biodistribution pattern would be a valuable future venture to 
undertake.  
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CHAPTER 7: DISCUSSION 
7.1 Study Summary 
 The scope of this dissertation covered the advancement of a novel 
nanoformulation for cancer treatment, MENs, from the knowledge that the treatment is 
effective in-vitro all the way to mapping the clearance of the treatment from fully cured 
animal patients in in-vivo studies.   
 First, we elaborated on the in-vitro mechanics of the treatment. This was done by 
treating cancer cells with the nanoformulation and an applied magnetic field, removing 
all solution from the cells, and finally bursting open the cells to locate the MENs inside. 
With this experiment, we were able to confirm that the MENs enter the cancer cells to 
deliver the carried drugs. Furthermore, the role of the magnetic field was investigated. 
We found that an externally applied d.c. magnetic field facilitated the internalization of 
the MENs into the cancer cell, likely by an electroporation mechanism at the nano scale. 
After the MENs had entered the cancer cells driven by the d.c. magnetic field, the 
application of an a.c. magnetic field triggered the release of the carried payload. 
Therefore, utilizing small, safe, externally controlled magnetic fields, we can trigger the 
internalization of the whole nanoformulation and later trigger the release of the molecule 
being delivered to the intracellular space.  
 Next, we treated a humanized murine model of cancer using the MEN treatment 
platform. Two different administration routes, three different nanoformulations, and the 
presence of d.c. and a.c. magnetic fields were all investigated in this initial study. It was 
determined that a systemic delivery was more effective than a localized delivery for the 
101 
MEN treatment, as more of the cancer cells are exposed to the treatment when it is 
carried by means of the vasculature as compared to when it simply flushes the periphery 
of the tumor. Compared to FDA approved organic nanoparticles (PLGA) and to similar 
magnetic nanoparticles that lack the electric properties of MENs (MNs), MENs were the 
strongest performing nanomedicine platform. MENs performed similarly with or without 
additional targeting via an external targeting molecule, while PLGA nanocarriers suffered 
in performance without these targeting molecules and MNs underperformed in general. 
The MENs treatment platform was the only platform able to fully cure the mice of their 
cancer in this study. Further investigation of the MEN platform highlighted the role of the 
MENs’ magneto-electric coupling. While particles that were too small to display the full 
scope of the magneto-electric coupling (10 nm MENs) remained unaffected, both 30 nm 
and the larger 100 nm MENs improved treatment efficiency with an a.c. magnetic field 
application following the d.c. magnetic field targeting treatment. This is likely due to the 
discreet functions of (1) MEN localization using a d.c. magnetic field application and (2) 
MEN-carried payload release using an a.c. magnetic field application, as were 
demonstrated in the in-vitro study previously. 
 Finally, we wanted to establish an understanding of the biodistribution and 
clearance of the MENs in the mice. We compared the mice from the cancer group treated 
over time to healthy mice which received a single high dose of the MENs and were 
mapped for nanoparticle distribution at varying time points post-injection. The cancer 
mouse group further highlighted the role of the applied magnetic field in the cancer 
treatment, as mice without any magnetic fields to induce the internalization of the 
treatment into the tumor had notably less MENs in the tumor and more in the periphery; 
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on the other hand, magnetic field treated mice had the largest portion of their MEN 
biodistribution localized in the tumor tissue. Mice successfully cured of their cancer had 
very little MENs remaining in their body after a three-month recovery period. The 
clearance times and varying MEN sizes revealed the following: 
1) 10 nm MENs clear the most rapidly, likely able to utilize some extent of renal 
clearance. 500 nm MENs had the lowest initial retention, however these large 
MENs were also the most numerous at the furthest time point in the study. 
2) The lung showed the highest initial retention of any peripheral organ, followed by 
transition into RES organs (i.e. the liver and the spleen) by all sizes. The RES is 
likely responsible for most of the MEN clearance. 
3) Very small amounts of the MENs were found in kidney and brain tissues 
throughout the entire study. 
 
Overall, these studies have shown that the previously reported efficacy of the MEN 
cancer treatment platform does indeed translate from in-vitro to in-vivo. Furthermore, the 
MEN drug delivery platform, which uniquely relies only on general physical properties, 
is the most effective of its kind, and the biodistribution and clearance patterns of this 
nanocarrier suggest clearance primarily through the reticuloendothelial system. 
7.2 Discussion 
7.2.1. The MEN Targeting Mechanism 
 One of the unique features of MENs is their ability to be influenced externally 
using spatial magnetic field gradients after administration to assist in guiding the particles 
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to the target site; this feature is shared with other types of strong magnetic nanoparticles 
as well. Non-magnetic nanoparticles that rely on either (a) the passive EPR effect, (b) 
active targeting by means of surface antibodies or ligands, or even (c) a combination of 
both are still limited in targeting potential in that they cannot be assisted towards the 
target site post-administration. The establishment of near perfect targeting capabilities is 
the goal of essentially any drug delivery platform, and magnetic field directed targeting is 
an additional feature held by magnetic nanoparticles that complements their inherent EPR 
and active targeting abilities. Active targeting molecules must be highly specific for 
different types of cancer, making this type of targeting less generalizable than the passive 
EPR and magnetic gradient targeting mechanisms. In a push for an adaptable cancer 
treatment, the physical accumulation of small molecules (i.e. the nanoformulation) by the 
EPR effect can be enhanced by further pooling the magnetic nanoparticle carried 
treatment at the general site of the tumor. With the magnetic nanoformulation being 
delayed in the vicinity of the tumor by means of an external magnetic field, the 
vasculature of the tumor has a greater opportunity to “leak” the nanoformulation into the 
tumor tissues by means of EPR. This more generalized (at least to solid tumors that 
establish an EPR effect) magnetic nanoparticle based treatment can then be further 
enhanced with active targeting molecules for greater specificity to individual cancer 
types.  
 MENs alone offer one additional targeting mechanism, which is not shared with 
any other nanoparticle based cancer treatment, and that is targeting by means of electric 
fields. Due to the varying cell membrane permeability to ions (such as Na+, K+, Ca2+, and 
Cl−)  that causes an uneven distribution of the ions, a voltage difference is established 
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between the intracellular and extracellular environment; this voltage (relative to the 
extracellular environment) is the membrane potential, and cancer cells are known to have 
a partially depolarized membrane potential favoring cell proliferation  [62], [88]. Since 
the cell membrane is an electrically polarizable medium, and cancer cells have distinctive 
electrophysiological properties, MENs can target cancer cells in a novel physical method 
that relies on the differences in these electrophysiological properties. 
 An intravenously administered MEN traveling through the circulatory solution 
(either blood or lymph) expresses its negative electric charge generated by means of the 
double layer colloidal chemistry on the MEN surface (zeta potential). This charge, 
combined with the smaller electric charge generated by the magneto-electric dipole, is 
amplified by an external magnetic field proportionally to the applied field strength, and 
allows the MENs to interface preferentially with the membranes of cancer cells. 
Therefore, an externally applied magnetic field creates a two-part cancer targeting 
mechanism for the MENs, as shown Figure 45. The first targeting mechanism is the 
simple magnetic pull of the MENs towards the tumor site, where higher chances of 
MEN-cancer cell interaction (leading to cellular internalization of the nanoformulation) is 
improved through increased MEN availability by means of accumulation at the vicinity 
of the tumor. The second targeting mechanism results from the MENs’ non-zero 
magneto-electric coefficient and is the amplification of the negative surface charge on the 
MENs by the externally applied magnetic field. In slightly alkaline cellular environments, 
like blood, cell membranes are typically exhibiting a negative electric charge [89]. This is 
advantageous to the MENs, as it establishes a negative-negative repulsion force that 
allows easier passage through the capillaries without being trapped by surrounding cells. 
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Considering that cancer cells have less negative membrane potentials compared to their 
healthy counterparts, the repulsion forces between MENs and cancer cells are weaker 
than the repulsion forces between MENs and healthy cells. Furthermore, when a MEN 
reaches the exterior of a cancer cell (through EPR, active targeting, and/or magnetic pull), 
the MEN’s surface charge can generate an electric field on the order of 1000 V/cm to 
create a localized nanoelectroporation effect. This nano-scale electroporation causes the 
cell membrane to locally rearrange the phospholipid bilayer at the immediate site of the 
nanoparticle, allowing the nanoparticle entry directly through the membrane. Due to the 
inherent differences in cell membrane properties between cancer cells and healthy cells, 
the electric field required to electroporate healthy cells is significantly higher (closer to 
the range of 5000–10,000 V/cm) [90], [91]. This difference in cellular electric properties 
allows healthy cells to be spared from MEN nanoelectroporation. 
 
Figure 45. MEN cancer targeting in circulation.  
Drug-loaded MENs traveling through the circulation are drawn to cancer cells with magnetic and electric 
fields. An applied magnetic field, H, pushes the MENs towards the site of the cancer. Additionally, the 
non-zero magneto-electric coefficient, α, influenced by H, polarizes the electric dipole, P, and increases the 
strength of the negative surface charge of the MEN. This creates a localized attraction force based on 
electric conductivity between the MENs and the cancer cells that is not shared by healthy cells. 
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 This hypothesis for in-vivo physical targeting is supported by the mouse trials, 
where we found that MNs were not able to readily localize into the tumor tissue despite 
their ~40x higher magnetization potential. This illustrates the importance of the magneto-
electric effect and surface charge manipulation by external magnetic fields in order to 
internalize the nanoformulation into the cancer cells. While the MNs were similarly 
drawn to the tumor with the externally applied magnetic field, it seems that the MNs were 
less capable of intracellular entry because of a lack of the nanoelectroporation effect; the 
MNs likely relied on the EPR effect. This also helps demonstrate that the magneto-
electric coupling of MENs grants a separate form of targeting that is complemented by, 
but not reliant on, the EPR effect. The electric field based discrimination of cancer cells 
by MENs allows this treatment to be applicable to cancers that lack a large, solid tumor 
with an established EPR effect, such as early-stage cancers or the metastasized cells of 
later-stage cancers. 
7.2.2. The MEN Payload Release Mechanism 
 Another unique advantage of the MEN platform is the capability to externally 
release the carried payload on demand. One of the primary challenges facing drug 
delivery platforms is a reliable release, one that is not premature and incomplete. The 
inherent properties of cancer physiology (i.e. the tumor microenvironment) offer some 
drug release options that are often utilized in nanomedicine [21]. Specifically, local tumor 
pH [92], [93] and tumor-prevalent enzymes [94], [95] are popular mechanisms for 
releasing drugs from nanocarriers. Drug release platforms relying on the minute 
differences of the tumor microenvironment suffer from non-ideal specificity, as the same 
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conditions can exist in normal physiological conditions (even if to a lesser extent) and are 
often too similar in parameters to reliably distinguish. For this reason, externally 
triggered drug release platforms are gaining favor, often in the form of heat generation 
[96] or ultrasound [97] drug release. Ultrasound drug release treatments tend to be 
utilized mostly for organic nanoparticle platforms. Temperature-reliant platforms in 
general tend to suffer from non-uniform heating, and any internal generation of heat has 
the potential to cause collateral damage to nearby healthy tissues. Our MEN platform 
offers a new externally controlled payload release mechanism based on magnetic field 
manipulation.  
 Figure 46 summarizes the entire multistep process of the MENs cancer treatment 
as pertaining to the external magnetic field manipulation. When no field is applied 
(Figure 46a), few MENs are able to internalize into cancer cells, although the small 
baseline magnetization of the MENs as well as passive EPR will likely allow a small 
portion of the treatment to internalize. In order for the MENs to nanoelectroporate and 
readily enter the cell, an external magnetic field which surpasses the electroporation 
threshold of the cell membrane must be applied (Figure 46b).  Again, it is important to 
stress that this electroporation threshold will be dramatically smaller for cancer cells than 
for healthy cells. The final step of payload release is then initiated by increasing the 
strength of the d.c. magnetic field being applied or by initiating an a.c. magnetic field 
application (Figure 46c). Applying magnetic fields to magnetic particles has the potential 
to generate heat, however Figure 47 shows the complete absence of heat generation in 
MENs throughout the entire field-exposure process. 
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a)      b)       c)    
Figure 46. Magnetic fields control MEN cellular entry and drug release. 
(a) When no field is present (H=0), very few MENs internalize into cells. (b) When the d.c. field is raised 
beyond the nanoeletroporation threshold field for the cancer cells (Hcell), the MENs readily cross the cell 
membrane and internalize. (c) When the MENs-drug bond release threshold (Hrelease) is surpassed, either by 
means of a stronger d.c. field or an a.c. field, the payload is released inside the cell. 
a)   b)   c)   
Figure 47. MENs generate no heat with applied fields. 
Cells incubated with MENs with (a) no field applied (b) 12 hour d.c. field application (c) 12 hour a.c. field 
application following 12 hour d.c. field application. No detectable changes in heat are observed. 
 
An a.c. field of approximately 50 Oe at 100 Hz is sufficient to release the PTX 
payload from the GMO coated MENs used in this series of experiments. This field 
strength is still far too weak to cause any notable interaction of MENs with healthy cells. 
The exact release threshold value will likely vary for different treatments loaded onto 
different functional coatings, but any MEN nanoformulation can be successfully 
delivered and the payload released with a correct combination of functional coating and 
applied magnetic field (Chapter 3.4). As long as the threshold to release the carried drug 
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is substantially higher than the threshold to enter the targeted cell (Hrelease > Hcell), the 
nanoformulation is viable for externally controlled targeting and payload release. Both 
Hrelease and Hcell must remain below the nanoeletroporation threshold field for healthy 
cells for healthy tissue to remain unharmed by the treatment.  
7.2.3 The MEN Clearance Mechanism 
We have found that our MENs appear to be primarily utilizing the RES (i.e. liver 
and spleen) for biological clearance, as deducted from robust presence in liver and spleen 
tissue and minimal presence in kidney tissue. This is consistent with the pore sizes 
associated with these organs. Renal clearance is such a fast and efficient process that 
evasion of renal clearance is actually a very valuable feature. Nanoparticles too large for 
renal clearance are able to remain in the blood plasma significantly longer than smaller 
molecules, and this is a critical component of the EPR effect [98]. The RES clears larger 
sized nanoparticles by means of Kupffer cells and macrophages [85]. Nanoparticles 
larger than 100 nm are reported to activate the classical complement pathway and 
macrophage internalization, both in a size dependent manner, with larger particles being 
recognized and cleared the fastest; however, the exact nanoparticle formulation as well as 
the surface charge also affects the rate of the mononuclear phagocyte clearance [99], 
[100]. Therefore, nanoparticles larger than 10 nm but smaller than 100 nm are considered 
to be in the ideal size range to evade both renal and RES clearance mechanisms long 
enough to benefit from EPR enhanced delivery. This is likely why our 30 nm MENs 
performed better than 10 nm and 100 nm sized MENs, both of which bordered on the size 
range required for renal and RES clearance, respectively. 
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Particles sized at approximately 500 nm and larger are not considered ideal for 
cancer treatment because their large sizes hinders their ability to benefit from the EPR 
effect in two ways: (1) the large size makes them candidates for rapid clearance from the 
body, not giving them enough time to localize into the tumor and (2) the leaky 
vasculature of the tumors more readily passes smaller nanoparticles into the internal 
tumor tissue. However, a larger size allows for potentially stronger physical properties 
(especially in the form of magnetics) to be displayed and for more elaborate payloads and 
targeting molecules to be loaded onto the surface. Therefore, particles of this size still 
merit investigation, as surface functionalizations can help alleviate rapid clearance issues 
and some tissues and tissue cancers have larger pores that can accept entry of molecules 
of this size. To eliminate a potentially strong magnetizer for the larger size seems 
premature in this case. The clearance by the macrophages of the RES is influenced by the 
protein absorption and opsonization of the nanoparticles, which is determined by physical 
attributes such as the particle’s surface chemical composition, surface charge, and 
hydrophobic/hydrophilic properties, as well as overall particle size and shape; every one 
of these properties can be modified, however, particles exceeding the nano-scale and 
entering the macro-scale mimic the size of bacteria and are cleared by macrophages with 
very high efficiency [99], [101], [102]. MENs can also be modified in surface properties, 
size, and shape to establish the desired effect while maintaining the desired 
biodistribution and clearance patterns. 
Inorganic or non-biodegradable nanoparticles tend to spark concern for long term 
retention. However, as long as there are no toxicity issues, long term nanoparticle bio-
retention is not necessarily a bad thing, as one of the primary principles of nanoparticle 
111 
drug delivery is the increase of the circulation time of the drug. Exceedingly rapid 
clearance of nanoparticles would hinder such goals. Any sort of longer term slow-release 
nanoformulation would absolutely benefit from clearance evasion and longer circulation 
and retention durations. MENs are a good candidate for slow-release nanoformulations 
for two primary reasons: (1) MENs effectively evade rapid clearance, as shown in 
Chapter 6, and (2) MENs are externally triggered to release their carried payload, as 
shown in Chapter 4. By adjusting the strength of the payload-releasing a.c. magnetic 
field, the release pattern can be slowed down to a trickle model instead of a burst model. 
Furthermore, a combination of functionalizations, such as those investigated in [64], can 
be utilized to establish MENs of different payload release strengths and combined into 
one long-term treatment. This slow-release MEN treatment would be composed of the 
differently functionalized MENs that are administered simultaneously, and targeted for 
internalization with a d.c. magnetic field simultaneously, but can then be activated to 
release their carried drugs at multiple different times by using different a.c. fields of 
gradually increasing strengths. 
7.2.4 MENs as an All-in-One Cancer Therapy 
 We have demonstrated here that our novel MEN cancer therapy is not only 
effective in-vivo, but holds many advantages over other nanoparticle based therapies. One 
such advantage is the multifaceted approach it can provide to patient care, as summarized 
in Table 9. MENs provide a reliable drug delivery and drug release platform that can 
simultaneously be used to monitor patient progress. 
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Table 9. MEN multifaceted cancer therapy.  
Cancer Targeting Drug Release Imaging 
Electric charge 
External DC Field Conventional MRI 
Magnetic pull 
Passive (EPR) 
External AC Field High Resolution MNI 
Active (antibody/ligand) 
 
 Furthermore, there is still room for customization in both the targeting and 
payload release parameters of the MENs. As shown in Chapter 5, MENs function with or 
without additional targeting molecules, and further targeting can be established with the 
addition of surface molecules as needed. Furthermore, as seen in the comparison of 
MENs to non-magnetoeletric MNs of the same size, it seems that MENs use a 
mechanism distinctive from EPR to reach the cancer cells, making the MENs treatment 
applicable beyond large, fixed tumor masses. Overall, MENs have the ability to utilize 
conventional nanoparticle targeting approaches while also boasting their unique electric 
field based cancer discrimination. The drug loading, and therefore the drug release, 
mechanism also has room for tailoring the platform to different drug formulations. As 
discussed in Chapter 3.4, different functional coatings can be utilized to provide 
distinctive surface properties and varying bond strengths with the payload. Depending on 
the bond strength between the MENs and the loaded drug, the magnetic field used to 
break that bond (Hrelease) can be adjusted accordingly. The MEN-payload bond can be 
broken using a stronger d.c. magnetic field than that used for the targeting (Hrelease > Hcell) 
or an a.c. magnetic field, which provides further options for customizing the 
nanoformulation. 
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 Lastly, MENs, like conventional magnetic nanoparticles, can safely be imaged 
using conventional MRI technology [54], [103]–[105], as well as newer, high-resolution, 
3D real-time magnetic nanoparticle imaging technology [56]. The implication for patient 
care is that the MENs can both deliver the desired treatment to the cancer and 
simultaneously serve as the contrast agent for imaging technology for live monitoring of 
treatment efficacy. For cancer treatment, MENs offer an unparalleled potential: 
1) Generally applicability to any cancer 
2) Multiple drug payload possibilities 
3) High specificity cancer discrimination 
4) Reliable externally controlled drug release 
5) Contrast agent capability 
6) General potential for further modifications for further specialization 
7) Overall a highly personalizable treatment that can be tailored to each patient 
For these reasons, we believe that the MENs platform has successfully answered the call 
to action by the national “Moonshot” initiative and has immense potential to be widely 
utilized in medical practice in the future. 
7.3 Future Studies 
This study established a general efficacy of this cancer treatment in-vivo as well 
as characterized the general biodistribution and clearance properties of the nanocarrier for 
the very first time. One of the obvious limitations is the small sample size. However, in 
consideration of maintaining the highest standard of animal research ethics, this study 
was deliberately kept small at this stage. The overwhelming success demonstrated by this 
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small pilot study warrants further investigation with larger cohorts to establish more 
precise pharmacokinetics, biodistribution, and clearance rates in general. Specifically, 
exact dose dependence should be established. It would also be interesting to compare 
cancer-treated mice to cancer-free mice for biodistribution with identical progressive 
dosages of MENs.  More animals dedicated to the cancer treatment experiment would be 
particularly valuable as there was notable heterogeneity of disease progression from the 
xenografts, which truthfully mimics the medical reality of human cancer patient diversity.  
Furthermore, the small size of nanoparticles grants them entry past the BBB and 
into the brain, making the use of nanoparticles for drug delivery to the brain a popular 
application of nanomedicine [106]. We would like to continue investigating the brain 
targeting potential of MENs first reported in a previous publication [6]. We have initiated 
a behavioral study component to the current study. While the mice used in this study 
appear to be completely unaffected by the MEN treatment (as determined by behavioral 
observation), a comprehensive, maze-based memory analysis will confirm any changes in 
cognition. It will also allow us to more accurately map the biodistribution of MENs 
throughout the brain. 
Finally, the treatment can be scaled up and investigated in a larger animal. The 
ultimate goal would be to progress this treatment into clinical trials, so any steps that 
need to be taken towards this goal are recommended as a future course of action. 
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